Market Signal Briefing

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

The cryptocurrency market is mainly green today, according to CoinStats.

Top coins by CoinStatsBTC/USDThe rate of Bitcoin (BTC) has risen by 3.7% over the past day.

Image by TradingViewOn the hourly chart, the price of BTC has made a false breakout of the local resistance of $106,482. If the daily bar closes far from it, traders may witness a correction to the $105,000 mark.

Image by TradingViewOn the longer time frame, the rate of the main crypto keeps going up after yesterday's bullish closure. However, buyers might need more time to accumulate energy for a further move. 

You Might Also Like

In this case, sideways trading in the range of $105,000-$108,000 is the most likely scenario.

Image by TradingViewFrom the midterm point of view, there are no reversal signals yet. The volume remains low, which means none of the sides is ready for a sharp move. In this regard, traders are unlikely to witness increased volatility soon. 

Bitcoin is trading at $105,945 at press time.

After a cryptic hint from Michael Saylor yesterday, Strategy went full throttle again—snapping up another pile of bitcoin ( BTC), precisely 487 BTC for just shy of $50 million. Strategy (Nasdaq: MSTR), once known as Microstrategy, added fresh bitcoin to its stash this week.

Mon, 10/11/2025 - 13:23

Shiba Inu layer-2 Shibarium has scored a brand new milestone, sparking interest from the community on what comes next for the blockchain.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

Shiba Inu layer-2 Shibarium has secured a new milestone, this time in total blocks. According to Shibariumscan, Shibarium has surpassed 14 million blocks, with total blocks now at 14,027,952.

UToday reported Shibarium being on the verge of this milestone over the week, with about 5,064 blocks left to reach the 14-million milestone at that time.

With the 14-million-block milestone now surpassed, this implies Shibarium added more than 5,000 blocks in a matter of days.

HOT Stories

Other Shibarium metrics have also shown a slight increase: total transactions are currently at 1,568,692,765; total addresses are at 272,745,593 and daily transactions showed a slight uptick from the past day, up from 1,660 to reach 2,970.

Shiba Inu price erases zeroCryptocurrencies continued to rise early Monday as investors became optimistic that the historic government shutdown might be nearing an end as lawmakers negotiate a deal.

The digital asset market enjoyed a period of upside over the weekend following two consecutive losing weeks. Bitcoin surpassed $106,000, with Shiba Inu also benefiting from the bullish momentum.

At press time, Shiba Inu was trading higher on both the daily and weekly time frames to $0.00001007, erasing a zero from its price tag. The altcoin market outperformed Bitcoin, with BTC dominance falling to 59.2% from the Nov. 5 high of 60.1%.

Shiba Inu bulls took a slight breather after Friday's surge, which took its price higher, from $0.00000902 to $0.00001034, in a single green daily candlestick, with the price consolidating in a range of $0.00000964 and $0.00001027. If Shiba Inu breaks out to the upside after its range trading, it might target $0.0000108 and $0.00001254 next.

On the other hand, if sellers gain a hold of the market, Shiba Inu would face its next support in the $0.000008 range.

Related articles

Strategic combination positions combined company to capture AI infrastructure demand at scale
Movano (Nasdaq: MOVE) shareholders gain exposure to rapidly emerging AI infrastructure pure play platform with differentiated product offering, a growing sales pipeline with attractive credit quality, leadership experienced in large-scale distributed computing and software development, and disciplined capital allocation
Merger exchange ratio based upon a Movano per share value of $6.25
Corvex, together with Movano, raised an aggregate of $40.0 million from concurrent private placement financings
Taking into account concurrent financings, Corvex shareholders to receive 46.6 million shares of Movano stock
Movano Health to resume process to market its medical device operations, including FDA-cleared EvieMED Ring and proprietary mmWave RF technology for cuffless blood pressure and noninvasive glucose monitoring

, /PRNewswire/ --Movano Inc. ("Movano") (Nasdaq: MOVE) and Corvex, Inc. ("Corvex"), an AI cloud computing company specializing in GPU-accelerated infrastructure for AI workloads, today announced a definitive agreement (the "Merger Agreement") to combine the companies in an all-stock transaction (the "Merger"). The Merger marks a key step in Corvex's plan to enter the public markets and underscores its emerging leadership addressing the three defining challenges of the AI era – more scale, more efficiency, and more security – via its Amplified AI CloudTM platform. As global demand for reliable and secure AI computing accelerates, Corvex offers investors differentiated exposure to the infrastructure layer powering the AI innovators of today and tomorrow.

"Today's announcement marks an important milestone for our company," said Jay Crystal, Co-Chief Executive Officer and Co-Founder of Corvex. "From day one, our success has been grounded in engineering excellence, an obsession with our customers' success, and disciplined capital allocation. Entering the public markets is a natural extension of this ethos—it allows us to accelerate our growth and craft a differentiated set of GPU-as-a-Service and AI-as-a-Service capabilities designed to attract customers with strong growth potential and credit quality. Over time, we plan to expand our AI factory offering's guaranteed power access to support even faster growth while also leveraging the magic of software to drive scalable growth in an asset-light fashion on third-party owned and operated hardware. We believe this barbell strategy will enable us to even more efficiently allocate capital across different segments of the market."

"The next wave of AI breakthroughs is expected to come from builders who can train, secure and accelerate models at the scale they need when they need it, all with absolute confidence in their infrastructure's reliability and the caliber of support available to ensure their success," said Seth Demsey, Co-Chief Executive Officer and Co-Founder of Corvex. "That's what our platform is designed for. We also have exciting emerging capabilities designed to extend the flexibility of our security capabilities in order to solve important scenarios for model builders and other security-conscious customers and, separately, an emerging offering designed to improve the cost- and performance-efficiency of inference. Ultimately, we're building the Amplified AI CloudTM that allows AI innovators to move faster, more securely and efficiently–and trust that it will just work."

"When we first met the Corvex team, it was immediately clear that they weren't just another AI infrastructure company—their ability to rapidly deliver power at up to AI factory scale, reliable operations, architectural creativity, software development and security know-how was extraordinary. We left that first meeting convinced that Corvex has the team, technology, discipline, and vision to quickly become an indispensable partner to attractive customer segments–and that our shareholders could share in that upside," said John Mastrototaro, Movano's Chief Executive Officer. "The combination of these two companies represents an exciting new chapter for our stockholders, further underscored by the highly experienced and well-regarded management team who will lead the combined company."

About Corvex

Corvex is an AI cloud computing company specializing in GPU-accelerated infrastructure for AI workloads. Corvex is based in Arlington, Virginia, and is led by Seth Demsey and Jay Crystal, Co-Chief Executive Officers and Co-Founders, and Brian Raymond, Chief Technology Officer. For more information on Corvex, visit https://corvex.ai.

About Corvex's Differentiated Product Suite

Corvex provides services that include:

AI Factories and GPU Clusters: GPU and CPU computing, storage, and networking, with a focus on AI model training and inference, operated with engineering excellence at up to AI factory scale. Delivered with managed Kubernetes or as bare metal, deployments can be operated in multi-tenant, single-tenant, or on-premise configurations that are compliant with HIPAA and SOC.
Confidential Computing: Hardware-backed Trusted Execution Environments ("TEEs"), memory encryption and attestation help safeguard data in use. Confidential computing is designed to protect customers' highly valuable intellectual property and enhance compliance with data security mandates.
Inference-as-a-Service: A next-generation platform being developed with endpoints powered by a performance-tuned inference engine, which is designed to increase throughput and reduce per-token costs.

Management and Organization

Following the merger, the combined company will be led by Seth Demsey and Jay Crystal, Co-Chief Executive Officers and Co-Founders of Corvex, Brian Raymond, Chief Technology Officer of Corvex, and other members of the Corvex management team. The leadership team has decades of experience in increasing positions of responsibility at firms like Google, Microsoft, Yahoo! / AOL, NASA's Advanced Computational Concepts Laboratory, investment banking and private equity, government contracting at ITT & Harris Corporation, and a startup that rapidly scaled by delivering high-performance computing and AI infrastructure worldwide. Collectively, the team has decades of experience in large-scale distributed computing, software development, mission-critical 24x7 large-scale distributed computing systems, and disciplined capital allocation. Upon consummation of the Merger, "Movano Inc." will be renamed "Corvex, Inc." and the corporate headquarters will be located in Arlington, Virginia. The board of directors of the combined company is expected to consist of six members, five of whom will be designated by Corvex and one of whom will be designated by Movano.

About the Proposed Merger

In connection with entry into the Merger Agreement, (a) Corvex has raised $37.1 million of equity capital in a private placement transaction (the "Corvex Concurrent Financing"); (b) Movano has entered into a $1.0 billion equity facility with Chardan Capital Markets LLC (the "Chardan Equity Facility"); and (c) Movano has raised $3.0 million of equity capital in a private placement transaction (the "Bridge Financing").

Upon the closing of the Merger, on a pro forma basis and prior to taking into account shares issuable by Movano pursuant to the Series A Purchase Agreement and the ChEF Purchase Agreement and shares issuable by Corvex in connection with the Corvex Concurrent Financing, based upon the number of shares of Movano Common Stock expected to be issued in the Merger, pre-Merger Corvex stockholders would own approximately 96.2% of the combined company and pre-Merger Movano stockholders would own approximately 3.8% of the combined company, in each case, on a fully-diluted basis (excluding out-of-the money options and warrants), subject to certain adjustments as described in the Merger Agreement. Under the Exchange Ratio formula in the Merger Agreement, the relative ownership of the combined company by Corvex's current stockholders and pre-Merger Movano shareholders will be adjusted to take into account funds raised in the Series A Purchase Agreement, the Chardan Equity Facility and the Corvex Concurrent Financing (based on a $6.25 post-Closing per share value). Taking into account the Bridge Financing and the Corvex Concurrent Financing (but excluding any capital that may be raised under the Chardan Equity Facility), it is anticipated that the combined company would have approximately 48.7 million shares outstanding. The Merger has been unanimously approved by the Board of Directors of both companies and is expected to close in the first quarter of 2026, subject to customary closing conditions.

Pursuant to the Merger Agreement, prior to completion of the Merger, Movano is permitted to market for sale its current operating assets, including the EvieMED Ring, which received U.S. Food and Drug Administration ("FDA") 510(k) clearance for its pulse oximetry feature, and proprietary mmWave radio frequency ("RF") technology for cuffless blood pressure and noninvasive glucose monitoring. To the extent it is able to sell such assets and realize net proceeds after paying off the balance due under its recently amended loan agreement and satisfying certain other reserve requirements, at the closing of the Merger Movano is permitted to distribute such net proceeds to pre-merger Movano shareholders.

Consummation of the Merger is subject to certain closing conditions, including, among other things, (a) approval by the requisite Movano and Corvex stockholders of the adoption and approval of the Merger Agreement, the Merger and the transactions contemplated thereby, (b) Nasdaq's approval of the listing of the shares of Movano Common Stock to be issued in connection with the Merger, (c) the effectiveness of a registration statement on Form S-4 to register the shares of Movano Common Stock to be issued in connection with the Merger, and (d) the absence of any orders or injunctions by any governmental entity that would prohibit consummation of the Merger.

Advisors

Chardan is acting as exclusive financial advisor to Corvex on the Merger and placement agent to Movano on the Bridge Financing. Jones is serving as an advisor to Corvex. K&L Gates LLP is serving as legal counsel to Movano. DLA Piper LLP (US) is serving as legal counsel to Corvex. Goodwin Procter LLP is serving as legal counsel to Chardan.

About Movano

Founded in 2018, Movano Inc. (Nasdaq: MOVE) dba Movano Health, maker of the Evie Ring (www.eviering.com), is developing a suite of purpose-driven healthcare solutions to bring medical-grade data to the forefront of wearables. On May 15, 2025, Movano announced its decision to initiate a process to explore strategic alternatives to maximize shareholder value. For more information on Movano, visit https://movanohealth.com/.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based upon current expectations or beliefs, as well as assumptions about future events. Forward-looking statements include all statements that are not historical facts and can generally be identified by terms such as "could," "estimate," "expect," "intend," "may," "plan," "potentially," or "will" or similar expressions and the negatives of those terms. These statements include, but are not limited to, statements relating to the proposed financing transactions discussed herein and the proposed Merger between Movano and Corvex (collectively, the "Proposed Transactions"); the structure, timing and completion of the proposed Merger between Movano and Corvex; the Proposed Transactions and the expected effects, perceived benefits or opportunities of the Proposed Transactions; the combined company's listing on Nasdaq after the closing of the Proposed Transactions; expectations regarding the structure, timing and completion of the Proposed Transactions, including investment amounts from investors, timing of closing of the Proposed Transactions, expected proceeds, expectations regarding the use of proceeds, and impact on ownership structure; the anticipated timing of the Closing; the expected executive officers and directors of the combined company; each company's and the combined company's expected cash position at the closing and cash runway of the combined company following the proposed Merger and the other financings discussed herein; the future operations and pipeline, estimates of financial position, competitive landscape, addressable market and strategic and financial initiatives of the combined company; the nature, strategy and focus of the combined company; expectations regarding the sale of Movano's legacy assets and its ability to repay the indebtedness under Movano's loan agreement with Evie Holdings LLC, as amended ("Loan Agreement"); the expectations regarding the ownership structure of the combined company; the expected trading of the combined company's stock on Nasdaq; and other statements that are not historical fact. All statements other than statements of historical fact contained in this press release are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are made based on current expectations, estimates, forecasts, and projections, as well as the beliefs and assumptions of management, concerning future developments and their potential effects. There can be no assurance that future developments affecting Movano, Corvex, or the Proposed Transactions will be those that have been anticipated.

Actual results could differ materially from those expressed in or implied by the forward-looking statements due to a number of risks and uncertainties, including but not limited to: the risk that the conditions to the Closing or consummation of the Proposed Transactions are not satisfied, including the failure to timely obtain approval of the proposed Merger from both Movano's and Corvex stockholders, if at all; the risk that the proposed financings are not completed in a timely manner, if at all; uncertainties as to the timing of the consummation of the Proposed Transactions and the ability of each of Movano and Corvex to consummate the Proposed Transactions; uncertainties as to the timing of the consummation of any Movano legacy asset sale; risks related to the outstanding indebtedness under the Loan Agreement and Movano's ability to satisfy its obligations thereunder; risks related to Movano's continued listing on Nasdaq until closing of the Proposed Transactions and the combined company's ability to remain listed following the Closing; risks related to Movano's and Corvex's ability to correctly estimate their respective operating expenses and their respective expenses associated with the Proposed Transactions, as applicable, pending the Closing, as well as uncertainties regarding the impact any delay in the Closing would have on the anticipated cash resources of the combined company, and other events and unanticipated spending and costs that could reduce the combined company's cash resources; risks related to the failure or delay in obtaining required approvals from any governmental or quasi-governmental entity necessary to consummate the Proposed Transactions; the occurrence of any event, change or other circumstance or condition that could give rise to the termination of the Merger Agreement; the effect of the announcement or pendency of the Merger on Movano's or Corvex's business relationships, operating results and business generally; costs related to the Merger; the risk that as a result of adjustments to the exchange ratio, Movano stockholders and Corvex stockholders could own more or less of the combined company than is currently anticipated; risks related to the market price of Movano's common stock relative to the value suggested by the exchange ratio; the indeterminate number of shares to be issued under the ChEF Purchase Agreement and the indeterminate proceeds under the ChEF Purchase Agreement; the outcome of any legal proceedings that may be instituted against Movano, Corvex or any of their respective directors or officers related to the Proposed Transactions; costs of the Proposed Transactions and unexpected costs, charges or expenses resulting from the Proposed Transactions; changes in regulatory requirements and government incentives; risks associated with the possible failure to realize, or that it may take longer to realize than expected, certain anticipated benefits of the Proposed Transactions, including with respect to future financial and operating results, legislative, regulatory, political and economic developments, and those uncertainties and factors; and the risk of involvement in litigation, including securities class action litigation, that could divert the attention of the management of Movano or the combined company, harm the combined company's business and may not be sufficient for insurance coverage to cover all costs and damages, and the other risks and uncertainties described in the Company's SEC reports, and under the heading "Risk Factors" in its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, which are available at www.sec.gov and in other filings that Movano makes and will make with the SEC in connection with the Proposed Transactions, including the Form S-4 and Proxy Statement described below under "Additional Information and Where to Find It". The forward-looking statements contained herein speak only as of the date of this report. Except as required by law, the Company does not undertake any obligation to update or revise its forward-looking statements to reflect events or circumstances after the date of this press release.

No Offer or Solicitation

This press release and the information contained herein is not intended to and does not constitute a solicitation of a proxy, consent or approval with respect to any securities or in respect of the Proposed Transactions or an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities pursuant to the Proposed Transactions or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, and otherwise in accordance with applicable law, or an exemption therefrom. Subject to certain exceptions to be approved by the relevant regulators or certain facts to be ascertained, the public offer will not be made directly or indirectly, in or into any jurisdiction where to do so would constitute a violation of the laws of such jurisdiction, or by use of the mails or by any means or instrumentality (including without limitation, facsimile transmission, telephone and the internet) of interstate or foreign commerce, or any facility of a national securities exchange, of any such jurisdiction.

Additional Information and Where to Find It

This press release relates to the Proposed Transactions involving Movano and Corvex and may be deemed to be solicitation material in respect of the Proposed Transactions. In connection with the Proposed Transactions, Movano intends to file relevant materials with the SEC, including a registration statement on Form S-4 (the "Form S-4") that will contain a proxy statement (the "Proxy Statement") and prospectus. This press release is not a substitute for the Form S-4, the Proxy Statement or for any other document that Movano may file with the SEC and/or send to Movano's stockholders in connection with the Proposed Transactions. MOVANO URGES, BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS TO READ THE FORM S-4, THE PROXY STATEMENT AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT MOVANO, CORVEX, THE PROPOSED TRANSACTIONS AND RELATED MATTERS.

Investors and stockholders will be able to obtain free copies of the Form S-4, the Proxy Statement and other documents filed by Movano with the SEC (when they become available) through the website maintained by the SEC at www.sec.gov. Movano's Internet website address is www.movanohealth.com. Movano's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are available free of charge through the investor relations page of its Internet website as soon as reasonably practicable after it electronically files such material with, or furnish it to, the SEC. Movano's Internet website and the information contained therein or connected thereto are not intended to be incorporated into this report.

Participants in the Solicitation

Movano, Corvex, and their respective directors and certain of their executive officers and other members of management may be deemed to be participants in the solicitation of proxies from Movano's stockholders in connection with the Proposed Transactions under the rules of the SEC. Information about Movano's directors and executive officers, including a description of their interests in Movano, is included in Movano's most recent Annual Report on Form 10-K for the year ended December 31, 2024. Additional information regarding the persons who may be deemed participants in the proxy solicitations, including the directors and executive officers of Corvex, and a description of their direct and indirect interests, by security holdings or otherwise, will also be included in the Form S-4, the Proxy Statement and other relevant materials to be filed with the SEC when they become available. These documents can be obtained free of charge from the sources indicated above.

SOURCE Movano

November 10, 2025 7:30 AM EST | Source: Great Pacific Gold Corp.
Vancouver, British Columbia--(Newsfile Corp. - November 10, 2025) - Great Pacific Gold Corp. (TSXV: GPAC) (OTCQX: GPGCF) (FSE: V3H) ("Great Pacific Gold," "GPAC," or the "Company") announces results from its expanded Phase 1 diamond drill program at its flagship Wild Dog Project ("Wild Dog" or the "Project"), located on the island of New Britain, East New Britain Province, Papua New Guinea ("PNG"). The Phase 1 program is focused on the Sinivit target, a portion of the 15km Wild Dog epithermal structural corridor.

Key Highlights:

WDG-12 intercepted two well mineralized structures:First Structure: 5.9 m @ 14.38 g/t AuEq from 123.2m (14.0 g/t Au, 0.18% Cu, 12.4 g/t Ag);Including: 2.5m @ 32.0 g/t AuEq from 126.6m (31.3 g/t Au, 0.28% Cu, 24.7 g/t Ag).Second Structure: 5.8 m @ 6.15 g/t AuEq from 177m (5.1 g/t Au, 0.54% Cu, 15.4 g/t Ag);Including: 3.0 m @ 10.9 g/t AuEq from 179m (9.1 g/t Au, 0.96% Cu, 28.5 g/t Ag).WDG-13 completed and intersected two mineralized zones characterised by quartz-sulphide veining and brecciation. Assay results are pending, and WDG-14 is currently in progress, targeting depth and strike extensions of the same structural corridor (see Figures 5 and 7).Second drill rig mobilization update: the second drill rig (dual purpose sonic / diamond) has been shipped and is on route to the project site. Camp construction for the expanded drilling crew is well underway with drilling expected to begin in December 2025.LiDAR survey results received: The program generated a Digital Terrain Model with sub-10 cm vertical accuracy, providing critical topographic control for geological modelling, drill planning, and infrastructure layout. The dataset is currently being further analyzed and used to support structural mapping and refine target definition across the broader Wild Dog district."The Sinivit target on the Wild Dog epithermal structural corridor continues to deliver high-grade results. In addition, we are starting to build an advanced understanding of the structural controls for mineralization at Sinivit. Holes WDG-08, 12 and 13 define a coherent high-grade pod within the broader Sinivit structure, with WDG-14 underway and continuing to test this area. Mineralization beneath the Northern Oxide area (10, 10A and 11) appears weaker, consistent with our current model and historical results. This variation is typical of epithermal systems near surface," stated Greg McCunn, CEO of GPAC.

"We are looking forward to the second drill rig arriving so we can begin testing the Sinivit area at depth as well as exploring some of the other high-priority epithermal targets that have been identified in the recently completed Mobile MT data analysis exercise."

WDG-12 Overview

Drill hole WDG-12 intersected two discrete zones of intense quartz-sulphide brecciation and veining hosted within strongly altered volcanic rocks of the Wild Dog corridor. The upper interval (123-129 m) comprises colloform to crustiform quartz-pyrite-chalcopyrite-sphalerite-tennantite veins with associated vuggy silica. The lower interval (177-183 m) consists of a clast-supported hydrothermal breccia with quartz-sulphide cement and strong chalcopyrite-pyrite mineralization, interpreted to represent a deeper boiling zone within the epithermal system. Both zones display clear structural control along steep, northeast-trending faults consistent with the Sinivit vein orientation and suggest multiple mineralizing pulses derived from a deeper magmatic source.

Zone 1 — High-Grade Epithermal Vein Zone

The first structure in WDG-12 intercepted a 5.9 m interval grading 14.38 g/t AuEq from 123.2 m, including 2.5 m @ 32.0 g/t AuEq from 126.6 m. This zone is characterised by banded quartz-sulphide veining, hosted within silicified volcanic breccia. The textures display colloform and crustiform quartz banding, with abundant sulphide-rich breccia zones indicating multiple pulses of hydrothermal fluid and localised boiling, features typical of the high-grade epithermal veins developed along the Sinivit structural corridor.

Figure 1: WDG-12 core from 125.37-128.92m (Zone 1) showing high-grade quartz-sulphide veins and gold grades up to 68.2 g/t Au.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_gpacfig1.jpg

Zone 2 — Quartz-Sulphide Breccia

The second mineralized zone in WDG-12, from 179.0-182.54 m, returned 5.8 m @ 6.15 g/t AuEq (5.1 g/t Au, 0.54% Cu, 15.4 g/t Ag), including 3.0 m @ 10.9 g/t AuEq (9.1 g/t Au, 0.96% Cu, 28.5 g/t Ag). The interval comprises a strongly mineralized quartz-sulphide breccia, with gold and copper values reaching up to 29.8 g/t Au and 3.1% Cu.

This section is dominated by clast-supported hydrothermal breccia cemented by chalcopyrite, pyrite, and quartz, crosscut by later quartz-pyrite-chalcopyrite veins. Textural evidence suggests multiple phases of brecciation and fluid reactivation, reflecting sustained hydrothermal activity and pressure cycling within the feeder system. The zone potentially represents a deeper, high-temperature structural conduit within the Sinivit system, where boiling and fluid mixing led to efficient precious and base metal deposition. Coarse sulphide bands, comb quartz textures, and carbonate infill confirm a structurally controlled feeder environment beneath the main Sinivit lodes.

Figure 2: WDG-12 core from 179.0-182.54 m (Zone 2) showing quartz-sulphide breccia with strong gold and copper grades up to 29.8 g/t Au and 3.1% Cu.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_gpacfig2.jpg

Figure 3: HQ drill core specimen from WDG-12 (181m) showing a dark grey to black clast-supported hydrothermal breccia cemented by chalcopyrite, pyrite, and quartz.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_gpacfig3.jpg

Figure 4: HQ drill core hand specimen from WDG-12 (179.6m) showing massive quartz-carbonate-sulphide veining with coarse chalcopyrite and pyrite, typical of a strongly mineralized vein zone within the Sinivit system.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_gpacfig4.jpg

Wild Dog Phase 1 Diamond Drill Program

The Phase 1 program commenced in May 2025 and is designed to test the Sinivit target, a 1.5 km strike length within the 15 km Wild Dog epithermal vein structural corridor (Figure 1). The high-grade nature of the system has already been confirmed by multiple strong intercepts.

In addition, MobileMT geophysical data has highlighted the exceptional scale of the epithermal system and the potential for a major porphyry copper-gold system adjacent to the veins — a setting analogous to the Wafi-Golpu deposit in PNG (mineralization at Wafi-Golpu is not necessarily indicative of mineralization at Wild Dog).

The expanded program now totals 28 diamond drill holes and is expected to continue into early 2026. Drilling to date has only tested a small portion of the mineralized corridor, which remains open to the north, south, and at depth. A second drill rig is in the process of being mobilized to site.

Figure 5: Long section through the Sinivit target area showing drilling completed to-date with key intervals.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_1b0517b794278805_006full.jpg

LiDAR Survey

A high-precision fixed-wing airborne LiDAR and large-format imagery survey covering 187 km² across the Wild Dog district was completed in September 2025. The program produced a sub-10 cm Digital Terrain Model (DTM), providing exceptional topographic control for geological modelling, drill planning, and infrastructure design.

Following the recent delivery of the raw LiDAR dataset, GeoCloud Analytics has been engaged to reprocess and interpret the point-cloud data from a geological perspective, enhancing the visibility of subtle surface features that are often smoothed out in standard "bare-earth" models. This work aims to identify historical artisanal workings, map structural lineaments, fault zones, bedding and intrusive contacts, and highlight potential new target areas for field verification.

The reprocessed products will include enhanced hillshades, structural interpretations, and shapefiles of mapped geological features across the Wild Dog district, forming a key foundation for upcoming mapping and drill-target generation. Current drill pad locations and drill traces on the LiDAR topography are shown in Figure 6.

Figure 6: LiDAR panel topography with drill pad locations and drill tracing for the Sinivit target - oblique view looking north-west.

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/11018/273784_1b0517b794278805_007full.jpg

Results

Since commencing in May 2025, GPAC has completed thirteen drill holes at Sinivit with hole fourteen underway. Details of the drilling are shown in Table 1 with key assay results received to-date are shown in Table 2.

Table 1: Wild Dog Drill Hole Details (PNG94 UTM Zone 56 coordinates).

Hole IDEastingNorthingRLDipAziMax 
Depth
(m)StatusWDG-01394358.3 9488853.5 945-50 115 40.1AbandonedWDG-02394426.09489024.2 900-53050124.6CompletedWDG-03394384.99488926.5924-50053127.6CompletedWDG-04394384.89488926.5 924-5075120.6CompletedWDG-05394384.89488926.5 924-50116105.9CompletedWDG-06394428.69488923.1911-5035269.0CompletedWDG-07394457.59489375.0993-61114201.3CompletedWDG-08394455.59489373.0993-57127224CompletedWDG-09394459.59489374.0993-5885203CompletedWDG-10394475.19489484.0965-58114220CompletedWDG-10A394476.19489484.0965-57114200.4CompletedWDG-11394474.19489484965-68114253.4CompletedWDG-12394413.79489301.5982-52113235.2CompletedWDG-13394408.59489301.2983-63102261.3CompletedWDG-14394389.29489995.91002-55103tbdIn progressTable 2: Wild Dog Drill Hole Key Assay Results (WDG-02 to WDG-09 results previously announced).

Hole IDFrom
(m)To
(m)Interval1 (m)Gold
(g/t)Silver
(g/t)Copper (%)Gold Eq.2
(g/t)WDG-02 65.072.07.05.4968.842.9610.91including65.067.02.010.73114.642.2315.53WDG-03 102.0104.32.31.686.480.121.94including103.55104.30.754.0510.900.174.45WDG-04 62.068.06.08.3127.562.3712.35including64.068.04.012.2536.761.7115.35including64.066.42.419.7657.752.5924.48WDG-0572.077.05.01.2811.710.251.80including72.075.03.01.9115.360.312.58WDG-0612.015.53.54.6148.364.8612.79 including13.714.30.67.4473.4010.4224.61WDG-07153.0163.010.02.9910.920.323.61 including153.0158.15.14.7714.540.545.79WDG-07 172.0173.21.27.3093.51.1410.17 including172.5173.20.712.00178.01.9417.10WDG-08 154.0162.48.446.4659.631.9050.12including154.0157.83.893.30128.724.74102.2including157.0157.80.8322.084.54.26329.65WDG-08 180.0188.08.01.954.190.132.20including180.0184.04.03.323.710.163.62WDG-09169.0174.05.04.497.600.214.91including169.0171.02.010.3115.00.4111.13WDG-09182.4185.02.62.7442.962.166.62including182.8184.31.54.1741.871.897.61WDG-10173.6175.62.01.7328.120.633.04WDG-10184.9185.20.34.2100.00.996.90WDG-12123.2129.15.913.9612.410.1814.38including126.6129.12.531.2924.680.2832.02WDG-12177182.85.85.1215.410.546.15including1791823.09.0628.480.9610.9Notes:

Drill highlights presented above are core lengths (true widths are not known at this time).Gold equivalent (AuEq) exploration results are calculated using longer-term commodity prices with a copper price of US$4.50/lb, a silver price of US$27.50/oz and a gold price of US$2,000/oz. No metallurgical testing has been carried out on Wild Dog mineralized samples. For AuEq calculations, recovery assumptions of Au 92.6%, Ag 78.0%, and Cu 94.0% were used based on K92 Mining's stated recovery results in an Updated Definitive Feasibility Study for the Kainantu mine.Qualified Person

The technical content of this news release has been reviewed, verified and approved by Callum Spink, the Company's Vice President, Exploration, who is a member of the Australian Institute of Geoscientists, MAIG, and a Qualified Person as defined by National Instrument NI 43-101 Standards of Disclosure for Mineral Projects. Mr. Spink is responsible for the technical content of this news release. Mr. Spink is not independent of the Company.

About Great Pacific Gold

Great Pacific Gold's vision is to become the leading gold-copper development company in Papua New Guinea ("PNG"). The Company has a portfolio of exploration-stage projects in PNG, as follows:

Wild Dog Project: the Company's flagship project is located in the East New Britain province of PNG. The project consists of a large-scale epithermal target, the Wild Dog structural corridor, stretching 15 km in strike length and potentially over 1,000 meters deep based on a recent MobileMT geophysics survey. The survey also highlighted the Magiabe porphyry target, adjacent to the epithermal target and potentially 1,000 meters in diameter and over 2,000 meters deep. Drilling of the epithermal structure on the Sinivit target has yielded high-grade results, including WDG-08 which intercepted 8.4 meters at 50 g/t AuEq from 154 meters. The current drilling program will extend into 2026 with second drill rig expecting to be operational in December 2025.

Kesar Project: located in the Eastern Highlands province of PNG and contiguous with the mine tenements of K92 Mining Inc. ("K92"), the Kesar Project is a greenfield exploration project with several high-priority targets in close proximity to the property boundary with K92. Multiple epithermal veins at Kesar are on strike and have the same orientation as key K92 deposits, such as Kora. Exploration work to date by the Company at the Kesar Project has shown that these veins have high grades of gold present in outcrop and very elevated gold in soil grades, coincident with aeromagnetic highs. The Company conducted a diamond drill program on key target areas at the Kesar Project from November 2024 to May 2025 and have developed a follow-up Phase 2 program for 2026.

Arau Project: also located in the Eastern Highlands province of PNG, the Arau Project is south of and contiguous to the mine tenements of K92. Arau contains the highly prospective Mt. Victor exploration target with potential for a high sulfidation epithermal gold-base metal deposit. A Phase 1 Reverse Circulation drilling program was completed at Mt. Victor in August 2024, with encouraging results. The Arau Project includes the Elandora licence, which also contains various epithermal and copper-gold porphyry targets.The Company also holds the Tinga Valley Project in PNG.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Great Pacific Gold cautions that all forward-looking statements are inherently uncertain and that actual performance may be affected by many material factors, most of which are beyond their respective control. Such factors include, among other things: risks and uncertainties relating to Great Pacific Gold's limited operating history, its exploration and development activities on its mineral properties and the need to comply with environmental and governmental regulations. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, Great Pacific Gold does not undertake to publicly update or revise forward-looking information.

Mineralization at the properties held by K92 Mining Inc. and at the Wafi-Golpu deposit is not necessarily indicative of mineralization at the Wild Dog Project.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/273784

Rese-cel data presented at multiple medical meetings demonstrated potentially transformative, drug-free clinical responses with a favorable safety profile for autoimmune patients supporting outpatient use All myositis patients in the Phase 1/2 DM/ASyS cohort with sufficient follow-up who would have met key criteria for the registrational cohort met the registrational, 16-week primary endpoint Planned BLA submission for rese-cel in 2027 based on 14-patient, single-arm DM/ASyS registrational cohort initiating enrollment this quarter within the RESET-Myositis™ trial FDA alignment on additional registrational cohort designs for RESET-SSc™ and RESET-SLE™ anticipated by year-end 2025 PHILADELPHIA, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a business update. “Our team continued to execute with discipline and precision to extend our leadership through the RESET™ clinical development program.

Charlotte, NC, Nov. 10, 2025 (GLOBE NEWSWIRE) -- FG Nexus (Nasdaq: FGNX, FGNXP) (the "Company" or "FG Nexus"), today announced that management will participate at the Cantor Crypto & AI/Energy Infrastructure Conference on November 10-12th, 2025 at the Ritz-Carlton Hotel in Miami.

Management will deliver a presentation on FG Nexus' ETH treasury strategy and its outlook on Ethereum's long-term role in shaping global financial markets. Management will also be available for one-on-one meetings during the conference. Investors may register for the conference here.

About FG Nexus

FG Nexus Inc. (Nasdaq: FGNX, FGNXP), (the “Company”), is on the Ethereum Standard, and singularly focused on becoming the largest corporate holder of ETH in the world by an order of magnitude. In order to enhance our ETH YIELD, the Company will stake and intends to implement other yield strategies while serving as a strategic gateway into Ethereum-powered finance, including tokenized RWAs and stablecoin yield.

The FGNX® logo is a registered trademark.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are therefore entitled to the protection of the safe harbor provisions of these laws. These statements may be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “budget,” “can,” “contemplate,” “continue,” “could,” “envision,” “estimate,” “expect,” “evaluate,” “forecast,” “goal,” “guidance,” “indicate,” “intend,” “likely,” “may,” “might,” “outlook,” “plan,” “possibly,” “potential,” “predict,” “probable,” “probably,” “pro-forma,” “project,” “seek,” “should,” “target,” “view,” “will,” “would,” “will be,” “will continue,” “will likely result” or the negative thereof or other variations thereon or comparable terminology. In particular, discussions and statements regarding the Company’s future business plans and initiatives are forward-looking in nature. We have based these forward-looking statements on our current expectations, assumptions, estimates, and projections. While we believe these to be reasonable, such forward-looking statements are only predictions and involve a number of risks and uncertainties, many of which are beyond our control. These and other important factors may cause our actual results, performance, or achievements to differ materially from any future results, performance or achievements expressed or implied by these forward-looking statements and may impact our ability to implement and execute on our future business plans and initiatives. Management cautions that the forward-looking statements in this press release are not guarantees of future performance, and we cannot assume that such statements will be realized or the forward-looking events and circumstances will occur. Factors that might cause such a difference include, without limitation, fluctuations in the market price of ETH and any associated impairment charges that the Company may incur as a result of a decrease in the market price of ETH below the value at which the Company’s ETH are carried on its balance sheet, changes in the accounting treatment relating to the Company’s ETH holdings, the Company’s ability to achieve profitable operations, government regulation of cryptocurrencies and online betting, changes in securities laws or regulations such as accounting rules as discussed below, customer acceptance of new products and services including the Company’s ETH treasury strategy, general conditions in the global economy; risks associated with operating in the merchant banking and managed services industries, including inadequately priced insured risks and credit risk; risks of not being able to execute on our asset management strategy and potential loss of value of our holdings; risk of becoming an investment company; fluctuations in our short-term results as we implement our business strategies; risks of not being able to attract and retain qualified management and personnel to implement and execute on our business and growth strategy; failure of our information technology systems, data breaches and cyber-attacks; our ability to establish and maintain an effective system of internal controls; the requirements of being a public company and losing our status as a smaller reporting company or becoming an accelerated filer; any potential conflicts of interest between us and our controlling stockholders and different interests of controlling stockholders; and potential conflicts of interest between us and our directors and executive officers.

Our expectations and future plans and initiatives may not be realized. If one of these risks or uncertainties materializes, or if our underlying assumptions prove incorrect, actual results may vary materially from those expected, estimated or projected. You are cautioned not to place undue reliance on forward-looking statements. Under U.S. generally accepted accounting principles, entities are required to measure certain crypto assets at fair value, with changes reflected in net income each reporting period. Changes in the fair value of crypto assets could result in significant fluctuations to the income statement results. The forward-looking statements are made only as of the date hereof and do not necessarily reflect our outlook at any other point in time. We do not undertake and specifically decline any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect new information, future events or developments.

Investor Contact
[email protected]

Media Contact
[email protected]

Event being held today at 8:00 a.m. ET in New York City features presentations from Ovarian Cancer Key Opinion Leaders, Clinicians, Statistical Experts, and IMUNON executives

Investors, stakeholders, analysts and those interested in advances in ovarian cancer treatment and women’s health are encouraged to attend, either In-person or virtually

LAWRENCEVILLE, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today is presenting an update on recent progress with its IMNN-001 development program for the treatment of newly diagnosed advanced ovarian cancer, including a review of positive data from the Company’s Phase 2 OVATION 2 Study and the minimal residual disease (MRD) study conducted in partnership with Break Through Cancer. The program will also include updates on trial activation and patient enrollment in the Company’s ongoing Phase 3 OVATION 3 pivotal trial.

“IMNN-001 represents a potential landmark breakthrough in the treatment of newly diagnosed ovarian cancer in combination with standard of care chemotherapy. Data thus far indicate that our novel immunotherapy has the potential to represent a major advance in treatment that can make a meaningful difference in the lives of thousands of women,” said Stacy Lindborg, Ph.D., President and CEO of IMUNON. “No other frontline ovarian cancer treatment has shown improvement in overall survival, which of course is the ultimate goal. We are very encouraged to see results from our Ovation 2 Study demonstrate that IMNN-001 treatment plus chemotherapy is associated with a 13-month improvement in overall survival with a highly favorable benefit-risk profile. The results from this landmark trial strongly support the advancement of IMNN-001 into our Phase 3 trial. We are excited to share the latest updates in today’s event and to review what’s ahead for this program.”

R&D Day Featured Speakers and Program Highlights:

Premal H. Thaker, M.D., Washington University School of Medicine, will discuss the significant continuing unmet needs in ovarian cancer, a devastating disease where patient outcomes and frontline standard of care treatment have not changed for about 30 years, and the promise IMNN-001 brings to these patients and clinicians. She will highlight the data from the Phase 2 OVATION 2 clinical trial, with results including: Broad impact observed with IMNN-001 treatment on important cancer-fighting cytokines, effectively turning the tumor microenvironment from “cold” to “hot” by activating both innate and adaptive immune systems, renewing the elusive promise of an immunotherapy for ovarian cancer.Data reinforcing the highly favorable benefit-risk and safety profile of IMMN 001.The remarkable median 13-month overall survival (OS) benefit observed with IMNN-001 plus standard of care (SoC) chemotherapy, an increase that is considered clinically meaningful compared to SoC alone. Amir Jazaeri, M.D., University of Texas MD Anderson Cancer Center, will discuss safety, tolerability and translational insights from the Phase 2 MRD study of IMNN-001, including: Rationale for the trial and the importance of frontline therapy as the best opportunity to achieve a cure for ovarian cancer.New translational data that clearly show IMNN-001 preferentially being taken up by macrophages within the peritoneal fluid and tumor tissue, which then induces a robust response and tumor microenvironment remodeling.New data further supporting the highly favorable benefit-risk and tolerability profile of IMNN-001.The positive tolerability profile of IMNN-001, including in combination with SoC chemotherapy plus bevacizumab and in the maintenance setting.
Giorgio Paulon, Ph.D., Berry Consultants, LLC, will review the Phase 2 and ongoing Phase 3 trial designs and the strength of evidence for IMNN-001 from a statistical perspective. He will highlight the well-precedented nature of the Phase 3 design with the FDA, which leverages an innovative, adaptive, event-driven approach aligned with prior successful oncology trials that resulted in full approval by FDA based on interim analyses of overall survival. This foundation, supported by conservative power assumptions drawn from Phase 2 data, strong simulation modeling and robust statistical properties, underpins the Phase 3 trial's high probability for success.

Douglas V. Faller, M.D., Ph.D., IMUNON, will share new data further demonstrating that IMNN-001 shifted the balance in favor of immune stimulation, remodeling the tumor microenvironment in favor of anti-tumor responses, which is established to be associated with better prognosis. He will share the rapid progress to-date on the Phase 3 trial of IMNN-001, including expansion to additional sites and enrollment exceeding the Company’s expectations, strong levels of support and interest from investigators and the scientific community, and key clinical and other milestones for the company moving forward.
A live webcast of the event and presentation materials will be available on the “Scientific Presentations” page of the IMUNON website at https://investors.imunon.com/scientific-presentations.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising. The second modality, PlaCCine®, is developed for the gene delivery of viral antigens that can elicit a strong immunological response.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently conducting a Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this news release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing of enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Contacts:

SPRINGDALE, Ark., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:

(in millions, except per share data)Fourth Quarter Twelve Months Ended  2025  2024  2025  2024Sales$13,860 $13,565 $54,441 $53,309        Operating Income$158 $525 $1,098 $1,409Adjusted1Operating Income (non-GAAP)$608 $512 $2,287 $1,820        Net Income Per Share Attributable to Tyson$0.13 $1.00 $1.33 $2.25Adjusted1Net Income Per Share Attributable to Tyson (non-GAAP)$1.15 $0.92 $4.12 $3.10 1 The Company reports its financial results in accordance with U.S. generally accepted accounting principles (GAAP). As used in this table and throughout this earnings release, adjusted operating income (loss) and adjusted net income per share attributable to Tyson (Adjusted EPS) are non-GAAP financial measures. Refer to the end of this release for an explanation and reconciliation of these and other non-GAAP financial measures used in this release to comparable GAAP measures.

Fiscal 2025 Highlights

Sales of $54,441 million, up 2.1% from prior year; Sales up 3.3% excluding impact of $653 million increase in legal contingency accruals, which was recognized as a reduction to SalesGAAP operating income of $1,098 million, down 22% from prior yearAdjusted operating income of $2,287 million, up 26% from prior yearGAAP EPS of $1.33, down 41% from prior yearAdjusted EPS of $4.12, up 33% from prior yearTotal Company GAAP operating margin of 2.0%Total Company adjusted operating margin (non-GAAP) of 4.1%Cash provided by operating activities of $2,155 million, down $435 million from prior yearFree cash flow (non-GAAP) of $1,177 million, down $281 million from prior yearRepurchased 3.5 million shares for $196 millionReduced total debt $957 millionLiquidity of $3.7 billion as of September 27, 2025 Fourth Quarter Highlights

Sales of $13,860 million, up 2.2% from prior year; Sales up 4.8% excluding impact of $355 million increase in legal contingency accruals, which was recognized as a reduction to SalesGAAP operating income of $158 million, down 70% from prior yearAdjusted operating income of $608 million, up 19% from prior yearGAAP EPS of $0.13, down 87% from prior yearAdjusted EPS of $1.15, up 25% from prior yearTotal Company GAAP operating margin of 1.1%Total Company adjusted operating margin (non-GAAP) of 4.3% "We delivered year-over-year growth in sales, adjusted operating income and adjusted earnings per share, reflecting the strength of our multi-protein, multi-channel portfolio," said Donnie King, President and CEO of Tyson Foods. "This fiscal year's progress demonstrates our commitment to operational excellence while meeting the evolving needs of our customers and consumers. As a world-class food company and recognized leader in protein, we remain focused on continuously improving the controllable aspects of our business and delivering shareholder value."

SEGMENT RESULTS (in millions)

Sales(for the fourth quarter and twelve months ended September 27, 2025, and September 28, 2024) Fourth QuarterTwelve Months Ended   VolumeAvg. Price  VolumeAvg. Price  2025  2024 ChangeChange2 2025  2024 ChangeChange2Beef$5,489 $5,261 (8.4)%17.0%$21,623 $20,479 (1.9)%9.0%Pork 1,414  1,438 (4.2)%11.6% 5,781  5,903 (1.7)%5.3%Chicken 4,411  4,251 3.7%0.1% 16,837  16,425 2.6%(0.1)%Prepared Foods 2,546  2,472 (1.7)%4.7% 9,930  9,851 (2.5)%3.3%International/Other 584  609 (2.2)%(1.9)% 2,291  2,353 (0.1)%(2.5)%Intersegment Sales (584) (466)n/an/a (2,021) (1,702)n/an/aTotal$13,860 $13,565 (1.6)%6.4%$54,441 $53,309 —%3.3% Operating Income (Loss)(for the fourth quarter and twelve months ended September 27, 2025, and September 28, 2024) Fourth QuarterTwelve Months Ended   Operating Margin  Operating Margin  2025  2024 2025 2024  2025  2024 2025 2024 Beef$(319)$(71)(5.8)%(1.3)%$(1,135)$(381)(5.2)%(1.9)%Pork (99) (16)(7.0)%(1.1)% (199) (40)(3.4)%(0.7)%Chicken 447  409 10.1%9.6% 1,427  988 8.5%6.0%Prepared Foods 143  203 5.6%8.2% 898  879 9.0%8.9%International/Other (14) — n/an/a 107  (37)n/an/aTotal$158 $525 1.1%3.9%$1,098 $1,409 2.0%2.6%
ADJUSTED SEGMENT RESULTS (in millions)

Adjusted Operating Income (Loss) (Non-GAAP)1(for the fourth quarter and twelve months ended September 27, 2025, and September 28, 2024) Fourth QuarterTwelve Months Ended   Adjusted Operating Margin (Non-GAAP)  Adjusted Operating Margin (Non-GAAP)  2025  2024 20252 20242  2025  2024 20252 20242 Beef$(94)$(71)(1.6)%(1.3)%$(426)$(291)(1.9)%(1.4)%Pork 31  19 2.0%1.3% 181  142 2.9%2.4%Chicken 457  356 10.4%8.4% 1,482  1,015 8.8%6.2%Prepared Foods 189  205 7.4%8.3% 913  905 9.2%9.2%International/Other 25  3 n/an/a 137  49 n/an/aTotal$608 $512 4.3%3.8%$2,287 $1,820 4.1%3.4% 2 Average Price Change and Adjusted Operating Margin (Non-GAAP) for the Beef and Pork segments and Total Company for the three months ended September 27, 2025 exclude the impact of $225 million, $130 million, and $355 million, respectively, of legal contingency accruals recognized as a reduction to Sales. Average Price Change and Adjusted Operating Margin (Non-GAAP) for the Beef and Pork segments and Total Company for the twelve months ended September 27, 2025 exclude the impact of $318 million, $380 million, and $698 million, respectively, of legal contingency accruals recognized as reductions to Sales. Average Price Change and Adjusted Operating Margin (Non-GAAP) for the Pork segment and Total Company for the twelve months ended September 28, 2024 exclude the impact of $45 million of legal contingency accruals recognized as reductions to Sales.

OUTLOOK
As of the most recently published data for fiscal 2026, the United States Department of Agriculture (USDA) indicates domestic protein production (beef, pork, chicken and turkey) will increase approximately 1% compared to fiscal 2025 levels. The following is a summary of the updated outlook for each of our segments, as well as an outlook for revenue, capital expenditures, net interest expense, liquidity, free cash flow, tax rate and dividends for fiscal 2026. Certain of the outlook numbers include adjusted operating income (loss) (a non-GAAP metric) for each segment. As our accounting cycle results in a 53-week year in fiscal 2026 as compared to a 52-week year in fiscal 2025, the fiscal 2026 outlook is based on a comparable 52-week year. The Company is not able to reconcile its full-year fiscal 2026 projected adjusted results to its fiscal 2026 projected GAAP results because certain information necessary to calculate such measures on a GAAP basis is unavailable or dependent on the timing of future events outside of our control. Therefore, because of the uncertainty and variability of the nature of and the amount of any potential applicable future adjustments, which could be significant, the Company is unable to provide a reconciliation for these forward-looking non-GAAP measures without unreasonable effort. Adjusted operating income (loss) should not be considered a substitute for operating income (loss) or any other measures of financial performance reported in accordance with GAAP. Investors should rely primarily on the Company’s GAAP results and use non-GAAP financial measures only supplementally in making investment decisions.

Beef
USDA projects domestic production will decrease approximately 2% in fiscal 2026 as compared to fiscal 2025. We anticipate adjusted operating loss between $(600) million to $(400) million in fiscal 2026.

Pork
USDA projects domestic production will increase approximately 3% in fiscal 2026 as compared to fiscal 2025. We anticipate adjusted operating income of $150 million to $250 million in fiscal 2026.

Chicken
USDA projects chicken production will increase approximately 1% in fiscal 2026 as compared to fiscal 2025. We anticipate adjusted operating income of $1,250 million to $1,500 million for fiscal 2026.

Prepared Foods
We anticipate adjusted operating income of $950 million to $1,050 million in fiscal 2026.

International/Other
We anticipate similar results from our foreign operations in fiscal 2026 on an adjusted basis.

Total Company
We anticipate total company adjusted operating income of $2.1 billion to $2.3 billion for fiscal 2026.

Revenue
We expect sales to be up 2% to 4% in fiscal 2026 as compared to fiscal 2025.

Capital Expenditures
We expect capital expenditures between $700 million to $1.0 billion for fiscal 2026. Capital expenditures include investments in profit improvement projects as well as projects for maintenance and repair.

Net Interest Expense
We expect net interest expense to approximate $390 million for fiscal 2026.

Liquidity
We expect total liquidity, which was $3.7 billion as of September 27, 2025, to remain above our minimum liquidity target of $1.0 billion.

Free Cash Flow
We expect free cash flow to be between $0.8 billion and $1.3 billion for fiscal 2026.

Tax Rate
We currently expect our adjusted effective tax rate to approximate 25% for fiscal 2026.

Dividends
Effective November 7, 2025, the Board of Directors increased the quarterly dividend previously declared on August 7, 2025, to $0.51 per share on our Class A common stock and $0.459 per share on our Class B common stock. The increased quarterly dividend is payable on December 15, 2025, to shareholders of record at the close of business on December 1, 2025. The Board also declared on November 7, 2025 a quarterly dividend of $0.51 per share on our Class A common stock and $0.459 per share on our Class B common stock, payable on March 13, 2026, to shareholders of record at the close of business on February 27, 2026. We anticipate the remaining quarterly dividends in fiscal 2026 will be $0.51 and $0.459 per share of our Class A and Class B common stock, respectively. This results in an annual dividend rate in fiscal 2026 of $2.04 for Class A shares and $1.836 for Class B shares, or a 2% increase compared to the fiscal 2025 annual dividend rate.

 TYSON FOODS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF INCOME
(In millions, except per share data)
(Unaudited)  Three Months Ended Twelve Months Ended September 27, 2025 September 28, 2024 September 27, 2025 September 28, 2024Sales$13,860  $13,565  $54,441  $53,309 Cost of Sales 13,134   12,505   50,879   49,682 Gross Profit 726   1,060   3,562   3,627         Selling, General and Administrative 568   535   2,121   2,218 Goodwill Impairment —   —   343   — Operating Income 158   525   1,098   1,409 Other (Income) Expense:       Interest income (16)  (29)  (73)  (89)Interest expense 106   130   449   481 Other, net —   (51)  (47)  (75)Total Other (Income) Expense 90   50   329   317 Income before Income Taxes 68   475   769   1,092 Income Tax Expense 10   111   262   270 Net Income 58   364   507   822 Less: Net Income Attributable to Noncontrolling Interests 11   7   33   22 Net Income Attributable to Tyson$47  $357  $474  $800         Net Income Per Share Attributable to Tyson:       Class A Basic$0.14  $1.03  $1.37  $2.31 Class B Basic$0.12  $0.92  $1.22  $2.06 Diluted$0.13  $1.00  $1.33  $2.25 Dividends Declared Per Share:       Class A$0.500  $0.490  $2.010  $1.970 Class B$0.450  $0.441  $1.809  $1.773         Sales Growth 2.2%    2.1%  Margins: (Percent of Sales)       Gross Profit 5.2%  7.8%  6.5%  6.8%Operating Income 1.1%  3.9%  2.0%  2.6%Net Income Attributable to Tyson 0.3%  2.6%  0.9%  1.5%Effective Tax Rate3 14.4%  23.3%  34.1%  24.8% 3 The effective tax rate for the twelve months ended September 27, 2025 is impacted by a $343 million goodwill impairment as the impairment charge is non-deductible for income tax purposes.

TYSON FOODS, INC.
CONSOLIDATED CONDENSED BALANCE SHEETS
(In millions)
(Unaudited)  September 27, 2025 September 28, 2024Assets   Current Assets:   Cash and cash equivalents$1,229 $1,717Accounts receivable, net 2,524  2,406Inventories 5,681  5,195Other current assets 482  433Total Current Assets 9,916  9,751Net Property, Plant and Equipment 9,204  9,442Goodwill 9,469  9,819Intangible Assets, net 5,624  5,875Other Assets 2,445  2,213Total Assets$36,658 $37,100    Liabilities and Shareholders’ Equity   Current Liabilities:   Current debt$909 $74Accounts payable 2,601  2,402Other current liabilities 2,879  2,311Total Current Liabilities 6,389  4,787Long-Term Debt 7,921  9,713Deferred Income Taxes 2,195  2,285Other Liabilities 1,926  1,801    Total Tyson Shareholders’ Equity 18,085  18,390Noncontrolling Interests 142  124Total Shareholders’ Equity 18,227  18,514    Total Liabilities and Shareholders’ Equity$36,658 $37,100  TYSON FOODS, INC.
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)  Twelve Months Ended September 27, 2025 September 28, 2024Cash Flows From Operating Activities:   Net income$507  $822 Depreciation and amortization 1,361   1,400 Deferred income taxes (76)  (45)Impairment of goodwill 343   — Gain on sale of storage facilities (107)  — Other, net 233   189 Net changes in operating assets and liabilities (106)  224 Cash Provided by Operating Activities 2,155   2,590     Cash Flows From Investing Activities:   Additions to property, plant and equipment (978)  (1,132)Purchases of marketable securities (66)  (38)Proceeds from sale of marketable securities 62   35 Proceeds from sale of storage facilities 252   — Proceeds from sale of business —   174 Acquisition of equity investments (11)  (29)Other, net 76   102 Cash Used for Investing Activities (665)  (888)    Cash Flows From Financing Activities:   Proceeds from issuance of debt 175   2,415 Payments on debt (1,262)  (1,641)Proceeds from issuance of commercial paper —   1,694 Repayments of commercial paper —   (2,285)Purchases of Tyson Class A common stock (196)  (49)Dividends (697)  (684)Stock options exercised 21   14 Other, net (18)  (45)Cash Used for Financing Activities (1,977)  (581)Effect of Exchange Rate Changes on Cash (1)  23 (Decrease) Increase in Cash and Cash Equivalents and Restricted Cash (488)  1,144 Cash and Cash Equivalents and Restricted Cash at Beginning of Year 1,717   573 Cash and Cash Equivalents and Restricted Cash at End of Period 1,229   1,717 Less: Restricted Cash at End of Period —   — Cash and Cash Equivalents at End of Period$1,229  $1,717  Non-GAAP Financial Measures

Adjusted Operating Income (Loss), Adjusted Income before Income Taxes, Adjusted Income Tax Expense, Adjusted Net Income Attributable to Tyson and Adjusted EPS, EBITDA, Adjusted EBITDA, net debt to EBITDA, net debt to Adjusted EBITDA and Free Cash Flow are presented as supplemental financial measures in the evaluation of our business that are not required by, or presented in accordance with GAAP. The non-GAAP financial measures are tools intended to assist our management and investors in comparing our performance on a consistent basis for purposes of business decision-making by removing the impact of certain items that management believes do not directly reflect our core operations on an ongoing basis. These non-GAAP measures should not be a substitute for their comparable GAAP financial measures. Investors should rely primarily on our GAAP results and use non-GAAP financial measures only supplementally in making investment decisions. We believe the presentation of these non-GAAP financial measures helps management and investors to assess our operating performance from period to period, including our ability to generate earnings sufficient to service our debt, enhances understanding of our financial performance and highlights operational trends. These measures are widely used by investors and rating agencies in the valuation, comparison, rating and investment recommendations of companies. Our calculation of non-GAAP measures may not be comparable to similarly titled measures reported by other companies and other companies may not define these non-GAAP financial measures in the same way, which may limit their usefulness of comparative measures.

Definitions

EBITDA is defined as net income before interest, income taxes, depreciation and amortization. Net debt to EBITDA (Adjusted EBITDA) represents the ratio of our debt, net of cash, cash equivalents and short-term investments, to EBITDA (and to Adjusted EBITDA). EBITDA, Adjusted EBITDA, net debt to EBITDA and net debt to Adjusted EBITDA are presented as supplemental financial measurements in the evaluation of our business.

Adjusted EBITDA, Adjusted Operating Income (Loss), Adjusted Income before Income Taxes, Adjusted Income Tax Expense, Adjusted Net Income Attributable to Tyson and Adjusted EPS are defined as EBITDA, Operating Income (Loss), Income before Income Taxes, Income Tax Expense, Net Income Attributable to Tyson and diluted earnings per share, respectively, excluding the impacts of any items that management believes do not directly reflect our core operations on an ongoing basis.

Free Cash Flow is defined as Cash Provided by Operating Activities minus payments for Property, Plant and Equipment.

TYSON FOODS, INC.
GAAP Results to Non-GAAP Results Reconciliations
(In millions, except per share data)
(Unaudited)

Results for the fourth quarter ended September 27, 2025 SalesCost of SalesSelling, General and AdministrativeGoodwill ImpairmentOperating
IncomeOther (Income) ExpenseIncome before Income TaxesIncome Tax ExpenseNet Income Attributable to TysonEPS ImpactGAAP Results    $158  $68 $10 $47 $0.13 Facility fire related costs
(insurance proceeds)5—(4)—— (4)(11) (15) (3) (12) (0.04)Brand and product line discontinuations—— 6— 6 —  6  2  4  0.01 Restructuring and related charges6—12 —— 12 —  12  —  12  0.03 Legal contingency accruals735540 —— 395 —  395  94  301  0.85 Product recall66(25)—— 41 —  41  11  30  0.09 Impairment of equity investments—— —— — 28  28  1  27  0.08 Adjusted Non-GAAP Results    $608  $535 $115 $409 $1.15            Results for the fourth quarter ended September 28, 2024 SalesCost of SalesSelling, General and AdministrativeGoodwill ImpairmentOperating
IncomeOther (Income) ExpenseIncome before Income TaxesIncome Tax ExpenseNet Income Attributable to TysonEPS ImpactGAAP Results    $525  $475 $111 $357 $1.00 Facility fire related costs
(insurance proceeds)5—(48)—— (48)(31) (79) (8) (71) (0.20)Brand and product line discontinuations—— 8— 8 —  8  2  6  0.02 Plant closure and disposal charges—27 —— 27 —  27  (10) 37  0.10 Adjusted Non-GAAP Results    $512  $431 $95 $329 $0.92  Results for the twelve months ended September 27, 2025 SalesCost of SalesSelling, General and AdministrativeGoodwill ImpairmentOperating
IncomeOther (Income) ExpenseIncome before Income TaxesIncome Tax ExpenseNet Income Attributable to TysonEPS ImpactGAAP Results    $1,098  $769 $262 $474 $1.33 Facility fire related costs
(insurance proceeds)5—(18)—— (18)(18) (36) 4  (40) (0.12)Brand and product line discontinuations—— 23— 23 —  23  6  17  0.05 Restructuring and related charges6—43 2— 45 —  45  4  41  0.11 Legal contingency accruals769840 —— 738 —  738  175  563  1.58 Plant closure and disposal charges8—17 —— 17 —  17  5  13  0.04 Goodwill and intangible impairments9—— —343 343 —  343  —  343  0.96 Product recall66(25)—— 41 —  41  11  30  0.09 Impairment of equity investments—— —— — 28  28  1  27  0.08 Adjusted Non-GAAP Results    $2,287  $1,968 $468 $1,468 $4.12            Results for the twelve months ended September 28, 2024 SalesCost of SalesSelling, General and AdministrativeGoodwill ImpairmentOperating
IncomeOther (Income) ExpenseIncome before Income TaxesIncome Tax ExpenseNet Income Attributable to TysonEPS ImpactGAAP Results     1,409   1,092  270  800  2.25 Facility fire related costs
(insurance proceeds)5—16 —— 16 (34) (18) (13) (5) (0.02)Brand and product line discontinuations—— 8— 8 —  8  2  6  0.02 Restructuring and related charges6—— 31— 31 —  31  8  23  0.06 Legal contingency accruals45129 —— 174 —  174  41  133  0.38 Plant closure and disposal charges—182 —— 182 —  182  36  146  0.41 Adjusted Non-GAAP Results    $1,820  $1,469 $344 $1,103 $3.10   TYSON FOODS, INC.
Adjusted Operating Income (Loss) Non-GAAP Reconciliations
(In millions)
(Unaudited)
 Adjusted Operating Income (Loss)(for the fourth quarter ended September 27, 2025) BeefPorkChickenPrepared FoodsInternational/
OtherTotalReported operating income (loss)$(319)$(99)$447$143$(14)$158 Less: Facility fire related costs
(insurance proceeds)5 —  —  — — (4) (4)Add: Brand and product line discontinuations —  —  6 — —  6 Add: Restructuring and related charges6 —  —  4 5 3  12 Add: Legal contingency accruals7 225  130  — — 40  395 Add: Product recall —  —  — 41 —  41 Adjusted operating income (loss)$(94)$31 $457$189$25 $608  Adjusted Operating Income (Loss)(for the fourth quarter ended September 28, 2024) BeefPorkChickenPrepared FoodsInternational/
OtherTotalReported operating income (loss)$(71)$(16)$409 $203$—$525 Add/(Less): Facility fire related costs
(insurance proceeds)5 —  —  (51) — 3 (48)Add: Brand and product line discontinuations —  —  6  2 — 8 Add/(Less): Plant closure and disposal charges —  35  (8) — — 27 Adjusted operating income (loss)$(71)$19 $356 $205$3$512  Adjusted Operating Income (Loss)(for the twelve months ended September 27, 2025) BeefPorkChickenPrepared FoodsInternational/
OtherTotalReported operating income (loss)$(1,135)$(199)$1,427$898 $107 $1,098 Less: Facility fire related costs
(insurance proceeds)5 —  —  — —  (18) (18)Add: Brand and product line discontinuations —  —  23 —  —  23 Add/(Less): Restructuring and related charges6 48  —  9 (26) 14  45 Add: Legal contingency accruals7 318  380  — —  40  738 Add/(Less): Plant closure and disposal charges8 —  —  23 —  (6) 17 Add: Goodwill and intangible impairments 343  —  — —  —  343 Add: Product recall —  —  — 41  —  41 Adjusted operating income (loss)$(426)$181 $1,482$913 $137 $2,287  Adjusted Operating Income (Loss)(for the twelve months ended September 28, 2024) BeefPorkChickenPrepared FoodsInternational/
OtherTotalReported operating income (loss)$(381)$(40)$988 $879$(37)$1,409Add/(Less): Facility fire related costs
(insurance proceeds)5 —  —  (70) — 86  16Add: Brand and product line discontinuations —  —  6  2 —  8Add: Restructuring and related charges6 4  1  2  24 —  31Add: Legal contingency accruals 45  73  56  — —  174Add: Plant closure and disposal charges 41  108  33  — —  182Adjusted operating income (loss)$(291)$142 $1,015 $905$49 $1,820  TYSON FOODS, INC.
EBITDA and Adjusted EBITDA Non-GAAP Reconciliations
(In millions)
(Unaudited)  Twelve Months Ended September 27, 2025 September 28, 2024    Net income$507  $822 Less: Interest income (73)  (89)Add: Interest expense 449   481 Add: Income tax expense 262   270 Add: Depreciation 1,093   1,159 Add: Amortization4 257   229 EBITDA$2,495  $2,872     Adjustments to EBITDA:   Less: Facility fire related costs (insurance proceeds)5$(36) $(18)Add: Brand and product line discontinuations 23   8 Add: Restructuring and related charges6 45   31 Add: Legal contingency accruals7 738   174 Add: Plant closure and disposal charges8 17   182 Add: Goodwill and intangible impairments 343   — Add: Product recall 41   — Add: Impairment of equity investments 28   — Less: Depreciation and amortization included in EBITDA adjustments10 (62)  (129)Total Adjusted EBITDA$3,632  $3,120     Total gross debt$8,830  $9,787 Less: Cash and cash equivalents (1,229)  (1,717)Less: Short-term investments —   (10)Total net debt$7,601  $8,060     Ratio Calculations:   Gross debt/EBITDA3.5x 3.4xNet debt/EBITDA3.0x 2.8x    Gross debt/Adjusted EBITDA2.4x 3.1xNet debt/Adjusted EBITDA2.1x 2.6x 4 Excludes the amortization of debt issuance and debt discount expense of $11 million and $12 million for the twelve months ended September 27, 2025 and September 28, 2024, respectively, as it is included in interest expense.
5 Relates to a fire at a Chicken production facility in the fourth quarter of fiscal 2021 and a fire at our production facility in the Netherlands in the first quarter of fiscal 2024 that we subsequently decided to sell.
6 Includes the Network Optimization Plan that commenced in fiscal 2025 and the 2022 Program which completed in fiscal 2024.
7 The three and twelve months ended September 27, 2025 include a $40 million charge related to the 2015 sale of our Mexico operation.
8 Includes China plant relocation remuneration and related EPS impact, net of $1 million associated with Net Income (Loss) Attributable to Noncontrolling Interests, for the twelve months ended September 27, 2025.
9 Goodwill impairment is non-deductible for income tax purposes.
10 Removal of accelerated depreciation of $39 million related to network optimization plan charges for the twelve months ended September 27, 2025 and $127 million related to plant closures and disposals for the twelve months ended September 28, 2024 as they are already included in depreciation expense. Removal of accelerated amortization of $23 million and $2 million related to brand discontinuation for the twelve months ended September 27, 2025 and September 28, 2024, respectively, as they are already included in amortization expense.

TYSON FOODS, INC.
Free Cash Flow Non-GAAP Reconciliation
(In millions)
(Unaudited)  Twelve Months Ended September 27, 2025 September 28, 2024Cash Provided by Operating Activities$2,155  $2,590 Additions to property, plant and equipment (978)  (1,132)Free cash flow$1,177  $1,458  About Tyson Foods, Inc.
Tyson Foods, Inc. (NYSE: TSN) is a world-class food company and recognized leader in protein. Founded in 1935 by John W. Tyson, it has grown under four generations of family leadership. The Company is unified by this purpose: Tyson Foods. We Feed the World Like Family™ and has a broad portfolio of iconic products and brands including Tyson®, Jimmy Dean®, Hillshire Farm®, Ball Park®, Wright®, State Fair®, Aidells® and ibp®. Tyson Foods is dedicated to bringing high-quality food to every table in the world, safely, and affordably, now and for future generations. Headquartered in Springdale, Arkansas, the company had approximately 133,000 team members on September 27, 2025. Visit www.tysonfoods.com.

Conference Call Information and Other Selected Data
A conference call to discuss the Company's financial results will be held at 9 a.m. Eastern Monday, November 10, 2025. A link for the webcast of the conference call is available on the Tyson Investor Relations website at https://ir.tyson.com. The webcast also can be accessed by the following direct link: https://events.q4inc.com/attendee/176837355. For those who cannot participate at the scheduled time, a replay of the live webcast and the accompanying slides will be available at https://ir.tyson.com. A telephone replay will also be available until December 10, 2025, toll free at 1-877-344-7529, international toll 1-412-317-0088 or Canada toll free 855-669-9658. The replay access code is 2866305. Financial information, such as this news release, as well as other supplemental data, can be accessed from the Company's web site at https://ir.tyson.com.

Forward-Looking Statements
Certain information in this release constitutes forward-looking statements as contemplated by the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, current views and estimates of our outlook for fiscal 2025, other future economic circumstances, industry conditions in domestic and international markets, our performance and financial results (e.g., debt levels, return on invested capital, value-added product growth, capital expenditures, tax rates, access to foreign markets and dividend policy). These forward-looking statements are subject to a number of factors and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statements. We wish to caution readers not to place undue reliance on any forward-looking statements, which are expressly qualified in their entirety by this cautionary statement and speak only as of the date made. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Among the factors that may cause actual results and experiences to differ from anticipated results and expectations expressed in such forward-looking statements are the following: (i) the effectiveness of financial excellence programs or operational optimization plans; (ii) access to, and inputs from, foreign markets together with foreign economic conditions, including currency fluctuations, import/export restrictions and foreign politics; (iii) global pandemics have had, and may in the future have, an adverse impact on our business and operations; (iv) cyber attacks, other cyber incidents, security breaches or other disruptions of our information technology systems; (v) risks associated with our failure to consummate favorable acquisition transactions or integrate certain acquisitions’ operations; (vi) the Tyson Limited Partnership’s ability to exercise significant control over the Company; (vii) fluctuations in the cost and availability of inputs and raw materials, such as live cattle, live swine, feed grains (including corn and soybean meal) and energy; (viii) market conditions for finished products, including competition from other global and domestic food processors, supply and pricing of competing products and alternative proteins and demand for alternative proteins; (ix) outbreak of a livestock disease (such as African swine fever (ASF), avian influenza (AI), New World screwworm or bovine spongiform encephalopathy (BSE)), which could have an adverse effect on livestock we own, the availability of livestock we purchase, consumer perception of certain protein products or our ability to conduct our operations; (x) changes in consumer preference and diets and our ability to identify and react to consumer trends; (xi) effectiveness of advertising and marketing programs; (xii) significant marketing plan changes by large customers or loss of one or more large customers; (xiii) our ability to leverage brand value propositions; (xiv) changes in availability and relative costs of labor and contract farmers and our ability to maintain good relationships with team members, labor unions, contract farmers and independent producers providing us livestock; (xv) issues related to food safety, including costs resulting from product recalls, regulatory compliance and any related claims or litigation; (xvi) compliance with and changes to regulations and laws (both domestic and foreign), including changes in accounting standards, tax laws, environmental laws, agricultural laws and occupational, health and safety laws; (xvii) the effect of climate change and any legal or regulatory response thereto; (xviii) adverse results from litigation; (xix) risks associated with leverage, including cost increases due to rising interest rates or changes in debt ratings or outlook; (xx) impairment in the carrying value of our goodwill or indefinite life intangible assets; (xxi) our participation in a multiemployer pension plan; (xxii) volatility in capital markets or interest rates; (xxiii) risks associated with our commodity purchasing activities; (xxiv) the effect of, or changes in, general economic conditions; (xxv) impacts on our operations caused by factors and forces beyond our control, such as natural disasters, fire, bioterrorism, pandemics, armed conflicts or extreme weather; (xxvi) failure to maximize or assert our intellectual property rights; (xxvii) effects related to changes in tax rates, valuation of deferred tax assets and liabilities, or tax laws and their interpretation; and (xxviii) the other risks and uncertainties detailed from time to time in our filings with the Securities and Exchange Commission, including those included under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in our most recent Annual Report on Form 10-K and Quarterly reports on Form 10-Q.

Media Contact: Laura Burns, 479-713-9890
Investor Contact: Jon Kathol, 479-290-4235Source: Tyson Foods, Inc.
Category: IR, Newsroom

LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic colorectal cancer enrolled in an ongoing U.S. Phase 1 clinical trialLYL273 is a GCC-targeted CAR T-cell product candidate armed with enhancements designed to improve CAR T-cell expansion and cancer cell killingLyell management will host an investor webcast at 8:30 AM ET today
SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has strengthened its solid tumor pipeline by acquiring global rights to LYL273 (formerly GCC19CART), a novel autologous guanylyl cyclase-C (GCC)-targeted CAR T-cell product candidate for the treatment of metastatic colorectal cancer (mCRC) and other GCC-expressing cancers, from Innovative Cellular Therapeutics (ICT). Patients with refractory mCRC treated with LYL273 in a Phase 1 clinical trial conducted in the United States (U.S.) achieved a 67% overall response rate and an 83% disease control rate (complete and partial response plus stable disease) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with a manageable safety profile at the highest dose level studied to date. LYL273 is a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration and cancer cell killing in the hostile solid tumor microenvironment.

"We rarely see such deep and durable responses in colorectal cancer patients treated with multiple prior lines of chemotherapy. The outcomes in this initial cohort of heavily pre-treated patients are very encouraging,” said Benjamin L. Schlechter, MD, Senior Physician in the Gastrointestinal Cancer Center, Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, Boston, MA, and lead investigator in the Phase 1 clinical trial. “Patients with metastatic colorectal cancer have a tremendous need for innovations like LYL273, and I look forward to partnering with the Lyell team as we work to rapidly deliver on the potential of this innovative cellular therapy for patients with advanced colorectal cancer.”

“The ability to treat solid tumors with an acceptable safety profile has become the holy grail for CAR T-cell therapy for cancer,” said Richard Klausner, MD, Lyell co-founder and Board Chairman, former Director of the National Cancer Institute and co-founder and former Director of Juno Therapeutics. “These impressive early results suggest we may be on the path to finally breaking the barrier for solid cancer.”

Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide, and the incidence of colorectal cancer is rising in people younger than 55 years old. Approximately 53,000 people are expected to die from CRC in the U.S. in 2025. With approved therapies, only six percent of patients with mCRC in the third- or later-line setting achieve partial or complete responses to their next line of therapy, and median overall survival is generally less than 12 months. GCC is a receptor that plays a key role in the regulation of intestinal electrolyte homeostasis. It is expressed on more than 95% of colorectal cancers and a majority of pancreatic adenocarcinomas. Its expression in healthy tissue is limited to the gastrointestinal tract, where it is sequestered by tight junctions from the circulation.

U.S. Phase 1 Clinical Trial Data

Dose-dependent clinical activity in 12 patients enrolled in a Phase 1 clinical trial in the U.S. are reported as of an October 28, 2025 data cutoff date. Six patients were treated at Dose Level 1 (1 x 106 CAR T cells/kg) and six patients were treated at Dose Level 2 (2 x 106 CAR T cells/kg). All patients received a single dose of lymphodepleting chemotherapy on Day -3, including cyclophosphamide, 300 mg/m2, and fludarabine, 30 mg/m2. RECIST 1.1 classification of imaging results is per local site review.

Across both dose levels, the overall response rate was 50% (6 of 12 patients) and the disease control rate was 83%. At the highest dose tested, Dose Level 2, the overall response rate was 67% (4 of 6 patients), including one patient with a pathological complete response, one patient with complete reduction in tumor volume of the target lesions (100% partial response), and two additional patients with confirmed partial responses. For patients treated at Dose Level 2, the disease control rate was 83%, and the median progression-free survival was 7.8 months.

The incidence and severity of treatment-related adverse events were higher at Dose Level 2 than at Dose Level 1. The most common treatment-related adverse events at Dose Level 2 were cytokine release syndrome in 83% (5/6) of patients (Grade 1, 67%; Grade 2, 17%) and diarrhea in 83% (5/6) of patients (Grade 1, 33%; Grade 2, 33%; Grade 3, 17%). Immune effector cell-associated neurotoxicity syndrome occurred in 33% (2/6) of patients (Grade 2, 17%; Grade 3, 17%) and resolved rapidly with treatment. One patient experienced a dose-limiting toxicity at Dose Level 2, including Grade 3 diarrhea, Grade 4 enterocolitis and death from fungal sepsis 48 days post-infusion. No Grade 3 or higher diarrhea has occurred in the last three patients treated since establishing an optimized management protocol for diarrhea, including prophylaxis.

“Lyell was founded to realize the full potential of cell therapy for solid tumors, which make up more than 90% of all cancers. We believe LYL273 has the potential to be a transformational advance in the treatment of colorectal cancer, an area of tremendous unmet need,” said Lynn Seely, MD, Lyell’s President and Chief Executive Officer. “We look forward to leveraging our expertise in T-cell biology and CAR T-cell clinical development to rapidly progress this program, as well as our two pivotal clinical trials evaluating ronde-cel for patients with relapsed or refractory large B-cell lymphoma.”

LYL273 was granted Fast Track designation for the treatment of mCRC by the U.S. Food and Drug Administration. The Phase 1 clinical trial is continuing to enroll patients with refractory mCRC to determine the recommended Phase 2 dose. The next data update from this clinical trial is expected in the first half of 2026.

Clinical proof-of-concept was initially demonstrated in an investigator-sponsored clinical trial conducted in China. Data from this clinical trial in 15 patients with mCRC were published in JAMA Oncology (September 2024).

Details of the Transaction

Under the terms of the definitive license agreement, Lyell will receive exclusive global rights, outside of mainland China, Hong Kong, Macau and Taiwan, to research, develop, manufacture and commercialize LYL273. ICT will receive an upfront payment of $40 million and 1.9 million shares of Lyell common stock. ICT is also eligible to receive additional cash and equity consideration, as well as royalties on future net sales. Additional cash consideration consists of a potential $30 million clinical milestone, up to $115 million in late-stage regulatory milestones and up to $675 million in commercial sales milestones. Additional equity consideration consists of up to 1.85 million shares of Lyell common stock upon achievement of certain clinical and late-stage regulatory milestones. Tiered royalties range from mid-single digits up to 10% on annual net sales in the U.S. and low to mid-single-digit royalties on annual net sales in other countries within the licensed territory.

Following the close of the transaction, Lyell expects its cash will be adequate to fund operations into 2027 through data and progress updates from the rondecabtagene autoleucel (ronde-cel) clinical program for patients with large B-cell lymphoma and additional clinical data from the Phase 1 clinical trial of LYL273.

The transaction will have a modest impact on operating expenses for 2025. As a result of continued prudent expense management, Lyell now expects net cash use in 2025 to be between $155 million and $160 million, excluding the $40 million upfront payment from the transaction, below its previous net cash use guidance of between $175 million and $185 million.

Skadden, Arps, Slate, Meagher & Flom LLP served as legal counsel to Lyell.

Conference Call Details

Lyell’s management will host an investor conference call and webcast beginning at 8:30 AM ET today. The webcast can be accessed here.

A replay of the event and presentation materials will be archived on the Investor page of the Lyell Website following the end of the event.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the potential clinical benefits and therapeutic potential of LYL273 and ronde-cel; statements made by our Chief Executive Officer and others; expectations around enrollment for, and the next data update from, the Phase 1 clinical trial of LYL273; Lyell’s expectation that its cash will be adequate to fund operations into 2027 and through data and progress updates from the ronde-cel clinical program and additional clinical data from the Phase 1 clinical trial of LYL273; Lyell’s estimated 2025 net cash use; Lyell’s ability to rapidly move forward the development of LYL273; and other statements that are not historical fact. These statements are based on Lyell’s current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: Lyell’s limited experience as a company in initiating and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell’s product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell’s product candidates; Lyell’s ability to submit planned INDs or initiate or progress clinical trials on the anticipated timelines, if at all; RMAT and Fast Track designations may not actually lead to faster development, regulatory review or approval process, and do not assure ultimate FDA approval; the significant uncertainty associated with Lyell’s product candidates ever receiving any regulatory approvals; Lyell’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; the complexity of manufacturing cellular therapies and Lyell’s ability to manufacture and supply its product candidates for its clinical trials; implementation of Lyell’s strategic plans for its business and product candidates; Lyell’s realization of the expected benefits of its strategic plans for its business and product candidates, including the license of LYL273; the potential reduction of Lyell’s cash resources and fluctuations in Lyell’s operating results and financial condition as a result of Lyell’s milestone, royalty and success payment obligations for LYL273; the sufficiency of Lyell’s capital resources and need for additional capital to achieve its goals; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, and any geopolitical instability; potential changes to U.S. drug pricing, including the potential for “most-favored nations” pricing limitations; other risks, including general economic conditions and regulatory developments, not within Lyell’s control; and other risks, including those described under the heading “Risk Factors” in Lyell’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Securities and Exchange Commission on March 11, 2025 and in Lyell’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, previously filed with the Securities and Exchange Commission on August 12, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law.

Contact

Ellen Rose
Senior Vice President, Communications and Investor Relations
[email protected]

Three Late Breaking Science Presentations from MAPLE-HCM Provide Additional Data Including Responder Analyses, Patient Reported Outcomes, and Cardiac Biomarkers 

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that additional data from MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) were presented in three Late Breaking Science sessions at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions 2025 in New Orleans, LA. Two of the presentations were simultaneously published in the Journal of the American College of Cardiology.1,2

“These additional analyses from MAPLE-HCM expand on the primary finding that aficamten is superior to metoprolol on exercise capacity, with new insights into the overall treatment effect of aficamten as well as its effect on symptoms and biomarkers in comparison to metoprolol,” said Fady I. Malik, M.D., Ph.D., Cytokinetics’ Executive Vice President of Research & Development. “What’s notable is patients treated with aficamten achieved a significantly greater number of clinical response categories compared with metoprolol, and that nearly 40% achieved significant improvements in patient reported symptoms.”

Responder Analysis Shows Significantly More Patients on Aficamten Achieved Positive or Complete Response Compared to Metoprolol

Andrew Wang, M.D., Cardiologist and Professor of Medicine, Duke University School of Medicine presented a pre-specified responder analysis from MAPLE-HCM evaluating five clinically relevant measures of disease burden: complete hemodynamic response, symptom improvement, cardiac biomarker response, enhanced exercise capacity and favorable cardiac remodeling. These results were also simultaneously published in the Journal of the American College of Cardiology.1

After 24 weeks of treatment, aficamten was associated with greater improvements than metoprolol in all outcome measures (all p<0.001) (Figure 1). Additionally, the proportion of patients who had a positive response (improvement in three or four clinical parameters) or a complete response (improvement in all five clinical parameters) was 78% in those receiving aficamten vs. 3% for those receiving metoprolol (p<0.001).

KCCQ, Kansas City Cardiomyopathy Questionnaire; LAVI, left atrial volume index; LVOT-G, left ventricular outflow tract gradient; NNT, number needed to treat; NT-proBNP, N-terminal pro–B-type natriuretic peptide; NYHA, New York Heart Association

As previously disclosed, in MAPLE-HCM the rate of adverse events (AEs) was similar between groups. At least one treatment-emergent AE was reported by 65 (73.9%) and 66 (75.9%) patients treated with aficamten and metoprolol, respectively. The most common AE reported in the aficamten group in excess of the comparator (>5%) was hypertension (9 [10.2%] patients on aficamten compared to 2 [2.3%] patients on metoprolol) and the most common AE reported in the metoprolol group in excess of the comparator was dizziness (15 [17.2%] patients on metoprolol compared to 5 [5.7%] patients on aficamten).

Analysis of Patient Reported Outcomes Expands on Effect of Aficamten on Patient Symptom Burden

Michael E. Nassif, M.D., Cardiologist, Saint Luke’s Mid America Heart Institute, Associate Professor of Medicine, University of Missouri Kansas City presented results from a pre-specified sub-study of two patient reported outcome instruments in MAPLE-HCM: the Kansas City Cardiomyopathy Questionnaire (KCCQ) and Seattle Angina Questionnaire Summary Score (SAQ). The results from this analysis were also simultaneously published in the Journal of the American College of Cardiology.2

At 24 weeks, treatment with aficamten resulted in significantly greater improvements than metoprolol in both KCCQ Overall Summary Score (KCCQ-OSS) (16.6 points vs. 8.9 points, respectively; between-group difference = 7.8 points [95% CI: 3.3 to 12.3; p=0.001]) and KCCQ Clinical Summary Score (KCCQ-CSS) (15.8 points vs. 8.7 points, respectively; between-group difference = 6.9 points [95% CI: 2.6 to 11.2; p=0.002]).

Aficamten was also associated with statistically significant improvements across all KCCQ domains (p<0.05). Patients on aficamten more frequently reported very large improvements in KCCQ-OSS, defined as ≥20-point improvement (38.6% vs. 18.4%; number needed to treat (NNT)=4.9), and were significantly less likely to experience a worsening in KCCQ-OSS than those treated with metoprolol (6.8% vs 18.4%; number needed to harm (NNH)=8.6).

A non-statistically significant trend for greater improvement in SAQ-SS was observed with aficamten (13.9 vs. 8.4 [adjusted between-group difference = 4.6 points; 95% CI: -0.3 to 9.5; p=0.063]), driven by a large and statistically significant improvement in the SAQ Physical Limitation Domain, where patients on aficamten improved by a mean of 18.7 points compared with 6.9 points for those on metoprolol (between-group difference = 10.1 points; 95% CI: 3.9 to 16.2; p=0.001). Changes in the SAQ Angina Frequency and Quality of Life Domains were similar between treatment groups.

Aficamten Associated with Statistically Significant Improvement in Cardiac Biomarkers Compared to Metoprolol

Neal K. Lakdawala, M.D., Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School presented a pre-specified supplemental analysis from MAPLE-HCM of the impact of treatment with aficamten compared to metoprolol on the cardiac biomarkers NT-proBNP and high sensitivity cardiac troponin I (hs-cTnI). At baseline, high NT-proBNP and high hs-cTnI, indicative of cardiac wall stress and myocardial injury, respectively, were strongly correlated and generally associated with worse diastolic dysfunction. After treatment for 24 weeks, aficamten was associated with a 73% reduction (p<0.001) from baseline in NT-proBNP compared to an increase of 42% observed in patients receiving metoprolol (-81% treatment effect, p<0.001). Similarly, aficamten was associated with a 43% reduction in hs-cTnI, compared to a 17% decrease for metoprolol (-28% treatment effect, p=0.001). Patients with the greatest reductions in NT-proBNP experienced greater improvements in peak oxygen uptake (pVO2) and ventilatory efficiency (VE/VCO2). Additionally, changes in NT-proBNP were correlated with reductions of left ventricular outflow tract gradients (LVOT-G) and improved health status (KCCQ-OSS).

About Aficamten

Aficamten is an investigational selective, small molecule cardiac myosin inhibitor discovered following an extensive chemical optimization program that was conducted with careful attention to therapeutic index and pharmacokinetic properties.3 Aficamten was designed to reduce the number of active actin-myosin cross bridges during each cardiac cycle and consequently suppress the myocardial hypercontractility that is associated with HCM. In preclinical models, aficamten reduced myocardial contractility by binding directly to cardiac myosin at a distinct and selective allosteric binding site, thereby preventing myosin from entering a force producing state.

The development program for aficamten is assessing its potential as a treatment that improves exercise capacity as measured by peak oxygen uptake (pVO2) and relieves symptoms in patients with HCM. Aficamten was evaluated in SEQUOIA-HCM, a positive pivotal Phase 3 clinical trial in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten received Breakthrough Therapy Designation for the treatment of symptomatic HCM from the U.S. Food & Drug Administration (FDA) and for the treatment of symptomatic obstructive HCM from the National Medical Products Administration (NMPA) in China.

Aficamten is also currently being evaluated in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM; CEDAR-HCM, a clinical trial of aficamten in a pediatric population with oHCM; and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM.

Disclaimer

This communication contains a summary of new data related to the clinical development of aficamten presented at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions and the American Heart Association Scientific Sessions 2025. Aficamten is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy have not been established. Aficamten is currently under regulatory review in the U.S, where the FDA is reviewing a New Drug Application (NDA) for aficamten with a Prescription Drug User Fee Act (PDUFA) target action date of December 26, 2025. Additionally, the European Medicines Agency (EMA) is reviewing a Marketing Authorization Application (MAA) for aficamten, and The Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) is reviewing an NDA for aficamten with Priority Review.

About Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle (myocardium) becomes abnormally thick (hypertrophied). The thickening of cardiac muscle leads to the inside of the left ventricle becoming smaller and stiffer, and thus the ventricle becomes less able to relax and fill with blood. This ultimately limits the heart’s pumping function, resulting in reduced exercise capacity and symptoms including chest pain, dizziness, shortness of breath, or fainting during physical activity. HCM is the most common monogenic inherited cardiovascular disorder, with approximately 280,000 patients diagnosed, however, there are an estimated 400,000-800,000 additional patients who remain undiagnosed in the U.S.4,5,6 Two-thirds of patients with HCM have obstructive HCM (oHCM), where the thickening of the cardiac muscle leads to left ventricular outflow tract (LVOT) obstruction, while one-third have non-obstructive HCM (nHCM), where blood flow isn’t impacted, but the heart muscle is still thickened. People with HCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease.7 People with HCM are at risk for potentially fatal ventricular arrhythmias and it is one of the leading causes of sudden cardiac death in younger people or athletes.8 A subset of patients with HCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics is readying for potential regulatory approvals and commercialization of aficamten, a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM. In addition, Cytokinetics is developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), ulacamten, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten, for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to any of our clinical trials, statements relating to the potential benefits of aficamten or any of our other drug candidates, or our ability to obtain regulatory approval for aficamten in any jurisdiction by any particular date, if ever. Cytokinetics' research and development activities; the design, timing, results, significance and utility of preclinical and clinical results; and the properties and potential benefits of Cytokinetics' other drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing, or production of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

References:

Wang, A, Garcia-Pavia, P, Masri, A. et al. Aficamten in Obstructive Hypertrophic Cardiomyopathy: A Multi-Domain, Patient-Level Analysis of the MAPLE-HCM Trial. JACC. 2025.Nassif, M, Garcia-Pavia, P, Masri, A. et al. Effect of Aficamten vs Metoprolol on Patient-Reported Health Status in Obstructive Hypertrophic Cardiomyopathy. JACC. 2025Masri A, et al. Safety and Efficacy of Aficamten in Patients with Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis from FOREST-HCM. J Card Fail. 2025Chuang C, Collibee S, Ashcraft L, et al. Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. J Med Chem. 2021;64(19):14142–14152. https://doi.org/10.1021/acs.jmedchem.1c01290CVrg: Heart Failure 2020-2029, p 44; Maron et al. 2013 DOI: 10.1016/S0140-6736(12)60397-3; Maron et al 2018 10.1056/NEJMra1710575Symphony Health 2016-2021 Patient Claims Data DoF;Maron MS, Hellawell JL, Lucove JC, Farzaneh-Far R, Olivotto I. Occurrence of Clinically Diagnosed Hypertrophic Cardiomyopathy in the United States. Am J Cardiol. 2016; 15;117(10):1651-1654.Gersh, B.J., Maron, B.J., Bonow, R.O., Dearani, J.A., Fifer, M.A., Link, M.S., et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260.Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21 A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8de3104b-50ad-4620-849f-73bfa6212075

Your vote is important no matter how many securities of the Company you hold. The Board recommends that Securityholders vote FOR the Arrangement Resolution.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

, /PRNewswire/ -- Taylor Morrison Home Corporation (NYSE: TMHC) ("TMHC") today announced that the cash tender offer (the "Offer"), commenced on November 3, 2025, by its wholly owned subsidiary, Taylor Morrison Communities, Inc. (the "Offeror"), to purchase any and all of the Offeror's outstanding 5.875% Senior Notes due 2027 (the "Notes"), expired at 5:00 p.m. New York City time on November 7, 2025 (the "Expiration Time").

According to D.F. King & Co., Inc., the tender and information agent for the Offer, valid tenders had been received at the expiration of the Offer in the amount and percentage set forth in the table below.

Issuer

Title of 
Security

CUSIP
Numbers(2)

Principal
Amount
Outstanding

Principal
Amount
Tendered

Percentage of
Principal
Amount
Tendered

Purchase
Price per
$1,000
Principal
Amount of
Notes

Taylor Morrison
Communities,
Inc. 

5.875% Senior
Notes due
2027(1)

87724RAA0
and
U8760NAA7

$500,000,000

$479,155,000(3)

95.83 %(3)

$1,023.07

___________________________________

(1)

The Notes are callable at a redemption price of 100.000% of the principal amount thereof, plus accrued and unpaid interest, starting on March 15, 2027.

(2)

No representation is made as to the correctness or accuracy of the CUSIP numbers listed in this press release or printed on the Notes. They are provided solely for the convenience of holders of the Notes.

(3)

No principal amount of the Notes tendered remain subject to the guaranteed delivery procedures described in the offer to purchase and the related notice of guaranteed delivery.

The Offeror expects to accept for purchase all Notes validly tendered and not validly withdrawn as of the Expiration Time and expects to make payment for any such Notes on November 10, 2025.

The Offeror will apply a portion of the proceeds from the issuance of $525.0 million aggregate principal amount of the Offeror's 5.750% senior notes due 2032 (the "New Notes"), which is expected to close on November 10, 2025, to the payment for all Notes to be purchased in the Offer together with cash on the balance sheet.

The Offer was made pursuant to the terms and subject to the conditions set forth in the offer to purchase and the related notice of guaranteed delivery, each dated as of November 3, 2025.

Following the settlement of the Offer, the Offeror intends to redeem any and all outstanding Notes that are not purchased in the Offer. Concurrently with the launch of the Offer, the Offeror issued a conditional notice of redemption to redeem any Notes that remain outstanding following the Offer, on or around December 2, 2025 (as such date may be extended to satisfy the condition to such redemption which is, receipt of funds from a senior notes offering in an amount, together with cash on hand, sufficient to redeem or repurchase all of the Notes, the Offeror's 6.625% Notes due 2027 and the 6.625% Notes due 2027 issued by William Lyon Homes, Inc. (a wholly owned subsidiary of the Offeror) (the "Redemption Condition")) with a portion of the net proceeds from such senior notes issuance, at the make-whole redemption price, plus accrued and unpaid interest to, but not including, the redemption date, in accordance with the terms of the indenture governing the Notes. This press release does not constitute a notice of redemption or an offer to purchase the Notes not purchased in the Offer.

J.P. Morgan Securities LLC has served as the exclusive dealer manager for the Offer and D.F. King & Co., Inc. has served as the tender agent and information agent for the Offer. Questions regarding the terms of the Offer may be directed to J.P. Morgan Securities LLC by calling (866) 834-4666 (toll-free) or (212) 834-7489 (collect).

This press release is neither an offer to purchase nor a solicitation of an offer to sell any securities. In addition, this press release does not constitute a notice of redemption under the indenture governing the Notes.

About Taylor Morrison

Headquartered in Scottsdale, Arizona, Taylor Morrison is one of the nation's leading homebuilders and developers. We serve a wide array of consumers from coast to coast, including first-time, move-up, luxury and resort lifestyle homebuyers and renters under our family of brands—including Taylor Morrison, Esplanade and Yardly. From 2016-2025, Taylor Morrison has been recognized as America's Most Trusted® Builder by Lifestory Research.

Forward-Looking Statements

This press release includes "forward-looking statements" including statements regarding the expected terms and timing of the senior notes offering and the Offer and the intended use of proceeds from the senior notes offering. These statements are subject to a number of risks, uncertainties and other factors that could cause our actual results, performance, prospects or opportunities, as well as those of the markets we serve or intend to serve, to differ materially from those expressed in, or implied by, these statements. You can identify these statements by the fact that they do not relate to matters of a strictly factual or historical nature and generally discuss or relate to forecasts, estimates or other expectations regarding future events. Generally, the words "anticipate," "estimate," "expect," "project," "intend," "plan," "believe," "may," "will," "can," "could," "might," "should" and similar expressions identify forward-looking statements, including statements related to expected financial, operating and performance results, planned transactions, planned objectives of management, future developments or conditions in the industries in which we participate and other trends, developments and uncertainties that may affect TMHC's business in the future. A detailed discussion of such risks and uncertainties is included in TMHC's Form 10-K, on file with the Securities and Exchange Commission, in the section titled "Risk Factors," as updated in our subsequent reports filed with the Securities and Exchange Commission. Any forward-looking statement made in this press release is based only on currently available information and speaks only as of the date on which it is made. TMHC undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise.

For information:

CONTACT:
Mackenzie Aron, VP Investor Relations
(407) 906-6262
[email protected] 

SOURCE Taylor Morrison Home Corp.

Continued progress across LOTIS-7 with updated data anticipated in 2025 and LOTIS-5 with topline data expected in 1H 2026 Updated data from Phase 2 IIT of ZYNLONTA®  plus rituximab in patients with r/r follicular lymphoma presented at the 22nd International Workshop on Non-Hodgkin Lymphoma Recent financing supports expansion of ZYNLONTA in anticipation of 2L+ DLBCL launch with strengthened balance sheet relative to previously disclosed cash runway into 2028 LAUSANNE, Switzerland , Nov. 10, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today reported financial results for the third quarter ended September 30, 2025, and provided operational updates. "The successful completion of our most recent PIPE financing strengthens our balance sheet and provides the resources to further invest in ZYNLONTA ®  as we anticipate advancing into earlier lines of therapy for DLBCL and into indolent lymphomas," said Ameet Mallik, Chief Executive Officer of ADC Therapeutics.

Cover image via U.Today

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

A renowned developer in the Dogecoin (DOGE) community, Mishaboar, has warned members of the community to be cautious. The crucial warning was shared in an update on X, as he believes that some people are trying to profit from the Dogecoin brand.

Call for vigilance in Dogecoin ecosystemNotably, Mishaboar charged DOGE holders and investors to avoid fake "official projects or organizations" that represent Dogecoin. He emphasized the decentralized nature of the meme coin, reminding holders that DOGE belongs to the community.

Hence, no single individual can claim to "officially" speak for Dogecoin, as that would be deceptive. Mishaboar noted that some centralized entities are leveraging the DOGE name to promote financial products like Dogecoin treasuries, exchange-traded funds (ETFs) and loan programs.

Dear Dogecoin, once again: there is no "official" organization or person representing Dogecoin.

Nobody and nothing can "officially" represent Dogecoin.

Any product pushed by somebody claiming to be "officially" representing Dogecoin is something you should stay away from.

— Mishaboar (@mishaboar) November 10, 2025 He refers to these projects as "risky IOUs" because holders give up their DOGE and are left with only a promise that they will get them back. In his view, this places the investor at a disadvantage as they lose control of their Dogecoin.

Mishaboar maintains that such companies behind these offerings could collapse, leading to a massive loss for Dogecoin investors.

"As a retail user, you should stay away from all this crap. Do not lose your money to spineless morons that care only about themselves," he stated.

Mishaboar subtly reminded investors in the meme coin to avoid greed traps or being swayed by strong emotional messages on easy returns on investment. It is a warning for investors to stay sharp and not fall prey to schemes that could rob them of their assets in the long term.

You Might Also Like

The developer’s warning might have been prompted by cases of fake schemes that ultimately defraud investors of their assets. Some malicious actors offer mouth-watering, easy returns just to get holders to part with their assets and make away with them later.

Dogecoin sees modest price surge amid market optimismMeanwhile, on the crypto market, the meme coin is performing well, as Dogecoin exchanges hands at $0.1830, which represents a 4.89% increase in the last 24 hours. DOGE previously hit a peak of $0.1835, a signal that the meme coin has the potential to climb further.

Trading volume has also been bullish and is currently up by 31.33% to $2.01 billion. The spike in volume could have been triggered by renewed optimism on ETF filings.

The broader crypto market is also reacting to positive news about efforts to end the ongoing U.S. government shutdown. Investors are interpreting it as a bullish development for digital assets.

The good news for Bitcoin (BTC +3.89%) is that it's still up about 10% for the year. The bad news, though, is that Bitcoin is definitely experiencing some intense turbulence right now. It's down nearly 20% during the past 30 days, and recently dipped below the psychologically important $100,000 price level.

Despite that, Bitcoin bulls continue to call for new highs before the end of the year. Chief among them is Michael Saylor, founder and executive chairman of Strategy (MSTR +1.99%). He's now calling for Bitcoin to hit $150,000 sometime within the next two months. And he's still expecting the world's most popular cryptocurrency to hit $1 million within the next decade. So is he right?

Institutional adoption of Bitcoin
There are several key catalysts for Bitcoin, according to Saylor. The biggest is institutional adoption. This refers to the willingness of big financial institutions and Wall Street banks to embrace Bitcoin. The more that they embrace Bitcoin, the more investment products they will create for customers, and the more they will help to cheerlead Bitcoin's upward price trajectory.

Image source: Getty Images.

According to Saylor, the involvement of big Wall Street banks in the crypto narrative has the potential to lead to a 10-fold increase in Bitcoin's price. That's enough to push Bitcoin from a price of $100,000 to $1 million. From there, the continued mainstreaming of Bitcoin on a global basis could put Bitcoin on a glide path to $20 million over the next two decades, Saylor says.

Today's Change

(

3.89

%) $

3965.54

Current Price

$

105973.00

Moreover, Bitcoin treasury companies -- led by Strategy -- continue to accumulate Bitcoin at a prodigious pace. Strategy, for example, now has a whopping 641,205 bitcoins on its balance sheet, equivalent to roughly 3% of all Bitcoin in circulation. Continued demand from these companies is going to exert strong upward pressure on price.

Pro-crypto policies of the Trump administration
The pro-crypto approach of the Trump administration is also helping to generate significant tailwinds for Bitcoin. Pro-crypto advocates have been installed at key regulatory posts, and the Treasury Department has even gone so far as to call Bitcoin a strategic asset. In March, it helped plan a Strategic Bitcoin Reserve to accumulate Bitcoin in the future.

That augurs well for the future of Bitcoin. Other nations have also taken steps to establish strategic Bitcoin reserves of their own, while also adopting pro-crypto legislation. In one speculative scenario, a Bitcoin arms race might break out, with nations racing to stockpile as much Bitcoin as they can.

Caveats for investors about Bitcoin
So what could possibly go wrong? As it turns out, a lot. Long-time Bitcoin investors are familiar with the boom-and-bust cycle that dominates crypto. Every four years, Bitcoin experiences a cataclysmic decline in price, sending skittish investors to the exits.

Almost exactly four years ago, Bitcoin began to crater, eventually leading to a 64% plunge in price in 2022. In 2018, Bitcoin suffered an even more severe tumble of 74%.

That's what makes the current Bitcoin situation so dicey. If history is any guide, the current Bitcoin four-year cycle should be ending sometime this year, or early next year at the very latest. It's quite conceivable that Bitcoin's rise to the $126,000 price level in early October was a final blow-off top, and it's all downhill from here for the next year or so.

What are the chances for Bitcoin to hit $150K?
At the beginning of the year, the consensus was that Bitcoin would easily double in price to hit the $200,000 mark in 2025. But that doesn't appear likely to happen. Michael Saylor -- arguably one of the biggest Bitcoin bulls on the planet, due to his firm's hefty stake in the cryptocurrency -- has seemingly already abandoned the $200,000 price target in favor of a $150,000 price target.

But even a price target of $150,000 may be too aggressive. Right now, in online prediction markets, traders are only giving Bitcoin less than a 10% chance of hitting that price point by the end of this year.

So if you're going to invest in Bitcoin now, be sure you're doing so for the long haul, and not because you're expecting a spectacular price recovery during the final two months of the year.

XRP recorded a strong upward move in the past 24 hours, rising 12% to trade at $2.53. During the same period, market capitalization increased from $135.83 billion to $152.41 billion, reflecting approximately $16.6 billion in new inflows.

XRP 1-day market cap price chart. Source: CoinMarketCap
Trading volume also climbed to $4.98 billion, up 91% day-over-day. As a result, XRP significantly outperformed the broader cryptocurrency market, which gained 4.94% on the day.

Why is XRP price up today?
A primary factor behind the rally is renewed progress toward XRP spot exchange-traded funds (ETFs). Five proposed XRP ETFs from issuers including Bitwise and Franklin Templeton appeared on the DTCC’s “active and pre-launch”list.

This development indicates that issuers have completed key operational and clearing preparations. Although this does not guarantee SEC approval, it suggests that products are structurally ready if approval is granted. In addition, Canary Capital’s CEO pointed to November 13 as a realistic window for possible launch activity.

Meanwhile, broader macro conditions shifted in favor of risk assets. The U.S. Senate passed legislation to prevent a government shutdown, ensuring continuity in regulatory review processes, including ETF evaluations. 

At the same time, discussion around the proposed “tariff dividend” contributed to improved market sentiment, even though the Treasury later clarified that the measure may take the form of tax adjustments rather than direct stimulus. Consequently, liquidity and confidence conditions strengthened across digital assets.

XRP price prediction and key technical levels to monitor
On the technical side, XRP broke above the 23.6% Fibonacci retracement level at $2.55, supported by elevated trading volume. The Relative Strength Index currently ranges between 45 and 49, which suggests upward momentum remains available without approaching overheated territory. As a result, traders are now observing $2.46 as the nearest support and $2.69 as the next meaningful resistance level.

XRP 1-day price chart. Source: Finbold
Looking ahead, on-chain analyst Ali Martinez noted that XRP continues to form a bullish flag on the higher timeframe chart. According to Martinez, a controlled pullback toward $1.90 may finalize the pattern structure. If this scenario plays out and a breakout confirms, the technical projection indicates a potential move toward $10 in the medium term.

WLFI is by far the top performer in the past 24 hours.

Bitcoin’s price went on a substantial run in the past 24 hours or so, surging from under $102,000 to a multi-day peak of over $106,500.

Many altcoins have followed suit with even more impressive gains, including XRP, which has risen by 12% daily to reclaim the $2.50 level.

BTC Above $106K
The previous business week was quite painful for the primary cryptocurrency. The downfall began on Monday morning when it was rejected at $111,000 and pushed south to under $104,000. Although it bounced off initially to over $106,000, the bears had a tight grip on the market and drove the asset south to under $100,000 for the first time since June.

Bitcoin bottomed at just under $99,000 on Tuesday, but the subsequent rebound was short-lived. It was stopped at $104,000 and driven back to a five-digit price territory by Friday. However, this recovery was more impressive and sustainable.

BTC jumped toward $104,000 once again on Friday, and even though it was halted there at first, it remained around $101,000-$102,000 during the weekend. A more notable leg up followed on Sunday afternoon after US President Trump promised a tariff dividend to almost all Americans of at least $2,000.

At first, bitcoin tapped $104,000 but kept climbing on Monday morning. It exceeded $106,000 and reached a multi-day peak of just over $106,500 earlier today. Its market cap has reclaimed the $2.1 trillion tag, but its dominance over the alts has declined to 57.5%.

BTCUSD. Source: TradingView
Big Gain Alts
The decreasing BTC dominance in times of market resurgance means that the alts have performed better. XRP is a prime example as it has soared by more than 12% in the past day and now sits well above $2.50. ETH has reclaimed the $3,600 level following a 6.5% increase, while SOL is close to $170 after a 7% pump.

ADA, HYPE, LINK, ZEC, BCH, and LTC are also well in the green. The double-digit price gainers club is also joined by APT, ENA, AAVE, XLM, HBAR, RENDER, UNI, PUMP, and WLFI, which actually led with a massive 31% surge.

The total crypto market cap has added $170 billion daily and is up to $3.680 trillion on CG.

Cryptocurrency Market Overview Daily. Source: QuantifyCrypto

The cryptocurrency market has opened the new week bullish. This is the first time it has done so in roughly five weeks, as the bearish trend had engulfed the market in recent weeks.

The U.S. crypto market nears a historic milestone as the first spot XRP ETFs may launch next week, with the DTCC listing five funds under its 'active and pre-launch' category.

Brian Njuguna2 min read

10 November 2025, 10:46 AM

Source: ShutterstockU.S. Spot XRP ETFs Poised for Launch Amid Growing Institutional MomentumThe cryptocurrency market is on the brink of a historic milestone as the first U.S. spot XRP ETFs could launch as early as next week. 

The Depository Trust & Clearing Corporation (DTCC) recently listed five spot XRP ETFs under its “active and pre-launch” category, signaling that the long-anticipated entry of XRP-based exchange-traded funds into the U.S. market may finally be imminent.

According to Coin Bureau, the newly listed XRP ETFs come from a mix of top financial institutions and crypto-focused managers, Bitwise, Franklin Templeton, 21Shares, Canary, and CoinShares. 

Source: DTCCTheir diverse strategies blend traditional investment expertise with deep crypto insight, appealing to both retail investors seeking XRP exposure and institutions seeking regulated crypto access.

Unlike futures-based ETFs, a spot ETF directly tracks XRP’s current market price, offering investors seamless exposure without dealing with wallets, private keys, or exchanges. The launch of spot XRP ETFs could boost liquidity, attract fresh capital, and bring greater transparency to the market.

Notably, the potential launch of XRP spot ETFs comes amid renewed market optimism, with XRP reclaiming the key price level of $2.50 and attracting growing institutional interest. If approved, these ETFs could accelerate adoption and solidify XRP’s position as a leading digital asset.

Market watchers have long expected a U.S.-regulated XRP spot ETF to provide a safer, more accessible alternative to direct crypto purchases. 

With the DTCC listing these ETFs, investors gain added legitimacy and confidence, as the products meet established clearing, settlement, and compliance standards, addressing key concerns around custody and security.

If launched, these spot XRP ETFs could redefine U.S. crypto finance, connecting traditional investors to the fast-growing digital asset market and offering a pivotal opportunity in the mainstream adoption of cryptocurrencies.

ConclusionIf DTCC-listed spot XRP ETFs move from pre-launch to live trading, it would be a watershed moment for crypto investing, offering regulated access, deeper liquidity, and stronger institutional legitimacy, while advancing the mainstream adoption of digital assets in U.S. finance.

ENRICH your inbox with our best storiesDon’t miss out and join our newsletter to get the latest,
well-curated news from the crypto world!

Brian Njuguna

Brian Njuguna is a seasoned crypto journalist at Coinpaper, specializing in blockchain innovation, market trends, and regulatory developments. With a background in economics and years of experience covering the digital asset space, Brian delivers sharp, data-driven insights that cut through the hype. His reporting bridges global crypto narratives with emerging market perspectives, making complex topics accessible to a wide audience.

Read more about

Latest Cryptocurrencies News TodayXRP (Ripple) News

Ribbita (TIBBIR) surged 21.5% to $0.365, nearing its $0.449 ATH as bullish sentiment and RSI momentum strengthen.Monero (XMR) trades at $416, up 24% this month, with $460 key to retesting its $518 all-time high.Railgun (RAIL) rose 51% in five days to $4.75 and could reach a new high if it breaks $5.14 resistance.The crypto market is beginning to show signs of improvement, propelled by the US Government Shutdown seemingly coming to an end after 40 days. This is pushing many altcoins upwards sharply.

BeInCrypto has analysed three such altcoins that could potentially reach a new all-time high if the bullish momentum sustains.

Sponsored

Sponsored

Ribbita By Virtuals (TIBBIR)TIBBIR price surged 21.5% in the past 24 hours, reaching $0.365 at the time of writing. The altcoin is now just 23% away from its all-time high (ATH) of $0.449, suggesting renewed investor confidence and strong bullish interest across the broader cryptocurrency market.

The ATH was recorded in late October before TIBBIR corrected, but the token now appears poised for another upward move. If it can hold $0.317 as a key support floor and break above the $0.400 resistance, it could reclaim its previous highs. The RSI remains in positive territory, indicating strong bullish momentum driving further gains.

Want more token insights like this? Sign up for Editor Harsh Notariya’s Daily Crypto Newsletter here.

TIBBIR Price Analysis. Source: TradingViewHowever, potential risks remain if investor sentiment weakens. Profit-taking or broader market corrections could push TIBBIR below the $0.317 support level. Losing this footing may trigger a decline toward $0.268 or even $0.231. This would invalidate the bullish thesis and delay any chance of retesting its all-time high.

Sponsored

Sponsored

Monero (XMR)XMR continues to attract investor attention, benefiting from growing interest in privacy-focused cryptocurrencies. The altcoin has surged 24% since the beginning of the month, currently trading at $416.

Just below the $418 resistance level, XMR remains approximately 24.6% away from its all-time high of $518, reached in May 2021. The Parabolic SAR indicator reflects an active uptrend, suggesting that continued momentum could drive prices higher. Flipping $460 into support would position XMR for a potential retest of its record high.

XMR Price Analysis. Source: TradingViewHowever, a correction remains possible if investors begin selling to secure short-term gains. Should selling pressure increase, XMR price could drop toward $364 or even lower to $322. Such a decline would invalidate the bullish outlook.

Railgun (RAIL)RAIL price is trading at $4.75, just below the $5.14 resistance level, after rising 51% in the past five days. The altcoin’s sharp rally reflects renewed investor interest and increasing market activity, suggesting bullish sentiment remains strong.

Currently, RAIL sits 49% below its all-time high (ATH) of $7.10, recorded roughly a month ago. Given its 51% weekly surge, the token could soon retest the ATH if it successfully breaks above the $5.14 resistance level. Sustained buying momentum could propel RAIL toward new highs, reinforcing bullish confidence.

RAIL Price Analysis. Source: TradingViewHowever, if RAIL price fails to overcome the $5.14 resistance—something it has struggled with previously—it risks a downward correction. A rejection could send the altcoin falling toward the $4.02 support or even lower to $3.12, completely invalidating the current bullish outlook.

Disclaimer

In line with the Trust Project guidelines, this price analysis article is for informational purposes only and should not be considered financial or investment advice. BeInCrypto is committed to accurate, unbiased reporting, but market conditions are subject to change without notice. Always conduct your own research and consult with a professional before making any financial decisions. Please note that our Terms and Conditions, Privacy Policy, and Disclaimers have been updated.

Why Trust CoinGape

CoinGape has covered the cryptocurrency industry since 2017, aiming to provide informative insights to our readers. Our journal analysts bring years of experience in market analysis and blockchain technology to ensure factual accuracy and balanced reporting. By following our Editorial Policy, our writers verify every source, fact-check each story, rely on reputable sources, and attribute quotes and media correctly. We also follow a rigorous Review Methodology when evaluating exchanges and tools. From emerging blockchain projects and coin launches to industry events and technical developments, we cover all facets of the digital asset space with unwavering commitment to timely, relevant information.

While the 7% surge in the last 24 hours may not make FUNToken the most trending crypto, it has shown the market the future potential upside it holds.

The utility crypto has had a tumultuous run as of late. However, that hasn’t stopped it from gaining ground on the intraday price charts. The community is now hoping that the momentum could continue in the long term.

However, the current price action suggests that there may be a breakout on the way.

FUNToken Price Analysis: Rising Triangle in the Hourly Chart Showcases a Bullish Confirmation Pattern
While the long-term price action of any asset at the moment is beholden to macroeconomic conditions, FUNToken’s hourly chart tells a different story.

Source: CoinMarketCap

As shown above, a clear ascending triangle has started to form, with $0.0024 being the main rejection point for the project. Provided that FUNToken does break out past this level, it could be possible for the FUN price to make a further upward move.

Currently trading above the $0.0022 level, and with a market cap of over $24.8 million, FUNToken is a low-cap investment option available for investors. Given that this utility token has continued to leverage its gaming attributes to get a boost in value, it is possible for it to gain more ground in the time to come.

What’s driving this micro-level growth? The obvious answer lies in the number of engaging competitions on social media. Much of the green candles in the FUN price chart started to appear after the announcement of its $5 million FUNToken giveaway, an event designed to reward the stakers.

🚀 The $5 Million $FUNToken Giveaway is LIVE!

💎 Stake your $FUN, hit price milestones, and claim your share of 💰 $5,000,000 in rewards!

🔥 Just HODL & Earn as $FUN grows 📈

👉 https://t.co/L3wg3wIgAS#FUNToken pic.twitter.com/nT0krvfwjX

— FUNToken (@FUNtoken_io) October 24, 2025

According to the official reward page, which is 5m.fun, the $5M Giveaway is designed to be more than a marketing event, but a way to turn the passive aspect of staking into an element of active contribution. Per the rules, every $FUN staked through the campaign is locked in a verified Ethereum smart contract, and when a price milestone is achieved, users will earn rewards proportional to the amount of tokens they staked.

The simple rules applied to this are as follows:

Participants earn based on how early and how much they stake.
Milestone unlocks (from $0.01 to $0.10 USDT) create measurable incentives tied to token performance.
Even if milestones aren’t hit before the timer ends, stakers receive interest rewards in $FUN, thereby ensuring no effort is wasted.

This is an approach that rewards users based on their contribution to the project and the price performance.

FUNToken Daily Analysis: FUN Still an Undervalued Asset
FUNToken has been active on the market since 2022. So when the price chart is zoomed out, it is clear that the entire ecosystem is undervalued. The RSI of 22 makes an obvious revelation that FUNToken is a massively undervalued asset.

Therefore, the intraday momentum is important for the token. Once the resistance level showcased in the intraday chart above is broken through, an upward momentum could follow. That could have a macro positive impact on the price chart and potentially push the RSI inside the normal zone.

Despite the Price Action, Community Outlook of the Project Remains Positive
From the price chart available on CoinMarketCap, it is easy to perceive FUNToken as an asset still considered a new player in the world of high-cap assets. However, it is its low-cap attribute, affordability, and utility-centric use case that continue to yield positive results among investors.

According to CoinMarketCap’s community sentiment, 84% of crypto enthusiasts have viewed this project positively and are bullish about its long-term prospects.

Factors that Could Help Push the FUNToken Price Upwards
FUNToken has already proven itself to be a different sort of asset given its propensity for engagement and its focus on growth. However, when it comes to the true factors responsible for pushing the FUN price to new heights, here are the following aspects to keep in mind.

Utility Focused Multi-Venue Reward Mechanism
FUNToken’s core design is based on a transactional and participation layer for the gaming economy. Its native digital token, FUN, has multiple functionalities. One is to simplify payments, and another is to push for a DAO that could improve transparency. The third attribute, however, is the most important, for it forms the foundation of why FUN is growing: rewarding loyalty.

For one, players are able to use $FUN to access engaging features and win prizes. Holders can stake $FUN to earn rewards, and developers gain incentives by integrating $FUN into on-chain gaming environments.

Turning Engagement into Scarcity Events
FUNToken’s recent $5M giveaway has shown how engagement can be turned into scarcity events. The entire focus of the $5M giveaway is to bring more stakers to lock their tokens, and as the tokens get locked, they become scarce. This scarcity has created a contraction in the supply that’s already showing an increase in the FUN price.

According to the latest update, over 33 million tokens have been staked already.

🔥 Over 33 MILLION+ $FUN STAKED and climbing fast! 🚀

The $FUN fam just hit another major milestone in the race toward the $5M rewards pool! 💰

Stake now and secure your share 👉🏻 https://t.co/mfM6CYXQP5#FUNToken

— FUNToken (@FUNtoken_io) November 9, 2025

While this is a limited-time event, one that will end on January 31st, 2026, the intraday price action suggests that this could be turned into a staple to push the FUNToken price further up.

Final Thoughts: Will the FUN Price Momentum Continue?
FUNToken has cleverly implemented a mechanism through its $5 million giveaway that, at least until the beginning of next year, could help generate positive price action on the intraday charts.

However, what looks to be a standard price jump powered by a short-term reward mechanism can add up in the future, creating a foundation for a more sustainable level of growth. Each token staked pushes the project toward long-term expansion, and each user engaged helps create a community of bulls that could help it weather the tide of a crypto winter when it arrives.

It creates a loop for a circular economy in which engagement is rewarded, bringing more engagement to push the price of the token further. While macro factors will continue to contribute, FUNToken has strengthened its community enough to sustain its momentum for the long term.

Bitcoin (BTC) rallied to $106,500 early on Monday following a trend breakout on Sunday. Can Bitcoin go higher, or are we about to see a rejection from the current position? 

Back to retest the trendline or horizontal support?

Source: TradingView

It’s all pretty much in the chart as to what probably happens next. It can be seen in the 4-hour chart above that the $BTC price took a quick turn back to the upside on Sunday when it perhaps looked more likely that the price was going back to the $100,000 horizontal support level for another retest.

Instead, the price rose steadily through Sunday before breaking out of the downtrend line at the end of the day. Monday morning has seen the price rise to the $106,000 horizontal level where it is currently struggling and looking likely to reject from here.

The Stochastic RSI indicators are just starting to roll over and back down, so the likelihood is that the $BTC price could either retest the descending trendline as support, or break through, or follow it down to the major $100,000 support level.

If the bulls do manage to push the price higher from here, it just becomes further overbought and the reckoning with the bears will just have to take place a bit higher up - possibly at $110,000.

Back to test 15-month trendline before major rally?

Source: TradingView

On the daily chart one can just about see the little trend break that is currently taking place. At the bottom of the chart, the RSI indicator has also just broken through a downtrend, suggesting that there may be more longevity in this move.

However, in the bigger picture this is just a bit more noise. The $BTC price would still be expected to come down that little bit further in order to make a retest of the major ascending trendline. Once that has occurred, all the boxes would then probably be ticked and a proper strong rally could then kick off.

Hash Ribbons indicator signals something big is coming

Source: TradingView

The above weekly chart for $BTC shows the entirety of the bull market so far. A rough trendline has been drawn in order to show that three big upside price waves have taken place. It could be contended that another big price wave exists right at the beginning of the bull market, but we are generally trying to show the waves on an ascending trendline.

The vertical green dotted lines in the chart show the Hash Ribbons buy signals. These buy signals are quite rare in the weekly time frame, and it can be seen that they roughly correspond to the end of one wave and the beginning of the next. 

The Hash ribbons indicator tracks the network hashrate, and triggers a buy signal when Bitcoin miners capitulate, causing the hashrate to drop sharply because of unprofitably mining. This normally combines with a low price and a beginning of network recovery, which normally leads to a rally in price.

An anomaly in the chart reveals that instead of 1 or 2 buy signals in a year, 2025 has received 3 buy signals, which has never before happened in such close proximity. 

The significance here is that miners have restarted mining not once, but three times, suggesting an accelerated hashrate rebound, therefore a deeper capitulation, but followed by a shallower recovery time.

Is another big price wave about to form? Wouldn’t this take the price beyond the 8-year ascending trendline, and in its turn cause a huge explosive rally to the upside? This bull market may be far from over.

Disclaimer: This article is provided for informational purposes only. It is not offered or intended to be used as legal, tax, investment, financial, or other advice.

TL;DR

Bitcoin surged above $106,000 in the past 24 hours amid rising optimism over the full reopening of the U.S. government.
Liquidity is building around the $110,000–$112,000 zone, where a breakout could speed up bullish momentum.
Altcoins delivered strong gains between 6% and 12%, signaling a clear return of risk appetite across the crypto market.

Bitcoin extended its climb on Monday, trading near $106,144 after a +4.38% daily increase. Growing confidence that the U.S. government will complete its reopening this week has boosted demand for risk assets, with crypto reacting quickly. Traders are now assessing whether this momentum can send Bitcoin toward fresh price targets before the end of the month, supported by increasing liquidity and renewed institutional interest.

The agreement in Washington to restore full federal operations has been welcomed as a tailwind for digital assets. The end of the shutdown would unlock billions of dollars in delayed Treasury flows and restore the release of key economic data used by institutional investors. Forecast platforms sharply increased the odds of a full reopening before mid-November. Historically, Bitcoin has posted outsized returns once uncertainty declines, making current conditions appealing for buyers.

Altcoins Extend Gains Across Major Sectors
The broader crypto market saw a coordinated rally. Over the past 24 hours, Ethereum (ETH) jumped +6.50% to $3,613, XRP soared +12.32% to $2.54, and Solana (SOL) gained +7.16% to $168.99. Cardano (ADA) climbed +8.56% to $0.5997 and Chainlink (LINK) advanced +9.16% to $16.52. Dogecoin (DOGE), TRON (TRX), BNB, and Hyperliquid (HYPE) also posted solid increases. Analysts note that this broad-based strength typically emerges when liquidity returns and interest in higher-beta assets grows.

Key Levels And Market Outlook
Technical traders are watching $107,000 as the next near-term barrier, with strong interest concentrated around $110,000–$112,000. A decisive move above that range could attract sideline capital and accelerate buying. Bitcoin remains above long-term moving averages, reflecting steady demand and a constructive trend.

U.S. equity futures also pointed higher, adding a supportive backdrop. With reduced political friction, improving liquidity conditions, and strong technical signals, digital assets appear well-positioned to extend their advance. A growing number of traders now expect Bitcoin to test $110,000 in the short term, with altcoins set to amplify the next stage of upside momentum.